Published in final edited form as:

Cryobiology. 2010 July ; 60(3S): S20–S35. doi:10.1016/j.cryobiol.2009.10.006.

Current State of Hypothermic Machine Perfusion Preservation of Organs: The Clinical Perspective

Michael J. Taylor^{1,2} and Simona, C. Baicu

Cell and Tissue Systems, N. Charleston, SC., USA

¹Adjunct Professor of Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA

²Adjunct Professor of Surgery, Medical University of South Carolina, Charleston, SC. USA

Abstract

This review focuses on the application of hypothermic perfusion technology as a topic of current interest with the potential to have a salutary impact on the mounting clinical challenges to improve the quantity and quality of donor organs and the outcome of transplantation. The *ex vivo* perfusion of donor organs on a machine prior to transplant, as opposed to static cold storage on ice, is not a new idea but is being re-visited because of the prospects of making available more and better organs for transplantation. The rationale for pursuing perfusion technology will be discussed in relation to emerging data on clinical outcomes and economic benefits for kidney transplantation. Reference will also be made to on-going research using other organs with special emphasis on the pancreas for both segmental pancreas and isolated islet transplantation. Anticipated and emerging benefits of hypothermic machine perfusion of organs are: i) maintaining the patency of the vascular bed, ii) providing nutrients and low demand oxygen to support reduced energy demands, iii) removal of metabolic by-products and toxins, iv) provision of access for administration of cytoprotective agents and/or immunomodulatory drugs, v) increase of available assays for organ viability assessment and tissue matching, vi) facilitation of a change from emergency to elective scheduled surgery with reduced costs and improved outcomes, vii) improved clinical outcomes as demonstrated by reduced PNF and DGF parameters, viii) improved stabilization or rescue of ECD kidneys or organs from NHBD that increase the size of the donor pool, ix) significant economic benefit for the transplant centers and reduced health care costs, and x) provision of a technology for *ex vivo* use of non-transplanted human organs for pharmaceutical development research.

Keywords

Hypothermic Preservation; Machine perfusion preservation; Organ storage; Clinical transplant outcomes; Ischemia; Hypoxia

© 2009 Elsevier Inc. All rights reserved.

Corresponding Author: Michael J. Taylor, Ph.D., V.P. Research and Development, Cell and Tissue Systems, 2231 Technical Parkway, Suite A., N. Charleston, SC 29406, USA, mtaylor@celltissuesystems.com, FAX: 843-722-6657.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

The advent of clinical organ transplantation in the 1960's accelerated an interest in preserving organs outside of the body and despite some much earlier studies, notably by Nobel prize-winner Alexis Carrel and Charles Lindbergh [24], which focused principally upon perfusion at physiological temperature, increasing attention was given to hypothermic preservation. At about the same time it was established that renal function could be maintained on a pump oxygenator, and the benefits of lower temperatures on oxygen demand and ischemic tolerance in the perfused kidney were recognized [33;100]. The conceptual basis for the application of hypothermic perfusion in renal transplantation was in large part due to the early contributions of the team of investigators led by Arthur L. Humphries at the Medical College of Georgia (MCG) in the 1970's. The worldwide prominence of this group in clinical kidney transplantation was partly due to their pioneering research on in vitro kidney preservation [65-68]. As part of this MCG program in Augusta, Ga., Armand Karow Jr. worked to develop a means to cryopreserve kidneys, hearts, pancreatic islets and many other tissues [75-77;99; 109;180]. Karow's vision at that time was for freezers filled with human organs for transplantation akin to a blood bank. While this vision remains to be fulfilled today, his contributions laid the foundations for ongoing research as discussed in other articles in this memorial issue of the journal. Nevertheless, in parallel with Karow's research interests in organ cryopreservation, the early foundations laid down by the MCG group in hypothermic perfusion preservation (HPP) of organs [3] has been developed to the point that today clinical application is not only a reality but, in the case of kidneys, is a preferred preservation modality for so-called "expanded criteria donor organs" - a concept that is discussed more below.

It is not our intent in this article to review the history of the development of hypothermic perfusion preservation of organs for transplantation since this has recently been covered in an excellent review in this journal by Fuller and Lee, to which the reader is referred [51]. Instead we aim to provide a complementary disposition focusing on the current state of the art of HPP, often referred to as hypothermic machine preservation (HMP), as it applies clinically to the different transplanted organs.

Scientific basis for HMP

A good deal is known about the effects of cold on cells since cooling has proved to be the foundation of nearly all effective methods of protecting, and preserving cells and tissues for applications such as transplantation. Transplantation science calls for effective methods of preservation since it is unavoidable that donor cells, tissues and organs are required to withstand a period of *ischemia* and *hypoxia* as part of any transplantation procedure when the blood supply is temporarily interrupted. The basis of this hypothermic protection is that cooling can help to combat the deleterious effects of ischemia, but the consequences of cooling are not exclusively beneficial such that hypothermic storage is a compromise between the benefits and detriments of cooling. A complete understanding of the effects of hypothermia on the perfused organ calls for examination of the events at the cellular level since this is where the pathophysiology of ischemia, hypoxia and even hypothermic stress is ultimately mediated. It is not within the realm of this article to give even a brief review of the principles known to provide the basis for hypothermic protection of *ex vivo* organs, but reference is made to other recent articles that serve this purpose [20;131;158-160].

In essence, excision of a tissue for transplantation means that ischemia is total and inevitable even though the period may be brief. An immediate consequence of cessation of blood supply to an organ is deprivation of the supply of oxygen to the tissues, but anoxia (total) or hypoxia (partial) is only one of the many consequences of a lack of blood supply. A multifactorial cascade of events ensues following the initiation of ischemia. The pivotal event is ATP

depletion, which occurs within the first few minutes of oxygen deprivation. This early event leads immediately to a shift from aerobic to anaerobic metabolism, which very quickly becomes self-limiting with the production of lactate and protons. Cell depolarization also occurs very early in the cascade leading to a breakdown of ion homeostasis, and a concatenation of other intracellular and membrane-associated events that eventually culminate in cell death by either apoptosis or necrosis. A rise in the intracellular concentration of protons and calcium is at the center of many of the mechanisms now recognized to be contributory to cell death as a result of ischemia [38;131;143;158].

The basic principle of cellular preservation for clinical application is to minimize the deleterious effects of ischemia and anoxia during the preservation interval. This can either be achieved pharmacologically by using a wide variety of cytoprotective drugs, and/or by reducing temperature. Interestingly, conventional wisdom teaches us that there is no single drug, or cocktail of drugs, that can so safely and effectively suppress metabolism and provide ischemic protection for multiple tissues and organs as the application of hypothermia can [138;139]. Here the focus will be confined to our ability as interventionalists to control the environment of cells to optimize hypothermic preservation. In this context HPP is based upon the fundamental premise that devices can be designed to facilitate the replacement of blood in the circulation of an *ex vivo* organ with specially designed fluids to maximize the protective effects of hypothermia on the ischemic tissue.

The fundamental basis of all biologic and chemical processes is molecular activity and mobility, which are governed by thermal energy, such that as temperature is lowered so molecular motion is slowed. The removal of heat from a system slows down both physical and chemical processes in proportion to the loss of heat, and therefore to the fall in temperature. Since the processes of deterioration associated with ischemia and anoxia are mediated by chemical reactions, it has proved well founded to attempt to prevent or attenuate these changes by cooling. Biochemical processes involve molecular interactions that are invariably catalyzed by enzymes in reactions that require energy input from cellular stores such as ATP or creatine phosphate. Cooling can affect all components of these reactions including the energy status of the substrate molecules, the stability of the enzyme protein, and the capacity of the cell to supply biological energy. Table 1 lists a catalogue of the most important effects of hypothermia in relation to ischemic events that forms the basis for hypothermic preservation of organs. A discussion of these effects is available in a variety of other publications [20;131;158-160].

Why perfuse? Continuous perfusion versus static cold storage

Reliance upon hypothermia to counteract the effects of ischemia during organ storage has traditionally involved two modes of preservation: simple static cold storage (SCS) and continuous hypothermic perfusion. SCS has undoubtedly been the most widely used technique due principally to its simplicity, convenience and relative cost compared with machine perfusion techniques, which are inherently more complex due to the requirement for specialized perfusion devices. In fact, based on 2006 data from the Organ Procurement and Transplantation Network (OPTN), only about 20% of all kidneys in the USA were preserved using HMP. Nevertheless, as illustrated in Fig 1 these proportions are changing due to a resurgence of interest in the relative merits of HMP as it applies to the potential “rescue” of so-called marginal donor organs, ECD organs, and even NHBD organs that are increasingly being adopted as a means to provide more organs for clinical transplantation. The strategic importance of this is discussed more fully in the next section.

In kidney preservation, both animal experiments and historical clinical studies have demonstrated that HMP provides better early graft function compared with SCS [107;117;

141;148;181]. Associated benefits of HMP are listed in Table 2, and are discussed below in the context of the current role of HMP in clinical organ transplantation.

Clinical need and role of hypothermic perfusion preservation

Clinical kidney and liver transplantation has evolved from an experimental procedure 50 years ago to the current treatment of choice for patients with end-stage organ disease where patient and graft survival rates exceed 90% per year. However, as illustrated in Fig 2 an ever increasing shortage of donor organs means that there is an increasing number of patients on the waiting lists for transplants such that future advances in this field are constrained by both the numbers of available organs and their quality. As a consequence, less-than-optimal donor organs are increasingly being used in an attempt to close the widening gap between supply and demand.

At the present time, with the exception of living, related donor-derived kidneys, most organs for transplantation are largely obtained from brain-dead but still heart-beating unrelated donors. The usual practice of using heart-beating donors greatly restricts the number of available organs. Many patients that die in hospital, or from trauma outside of the hospital, have potentially usable organs, particularly kidneys, which cannot be used because of uncertainty regarding their quality. In the last decade Organ Procurement Organizations (OPOs) and transplant centers began evaluating and expanding their acceptability criteria of organs from cadaver donors. The most common reluctance noted in establishing this practice was organ evaluation and cost [71]. The ability to evaluate transplantable organs from expanded criteria - defined by the advanced age of the donor or additional donor risk factors such as hypertension and diabetes - and asystolic donors by machine *in-vitro* perfusion may significantly increase the number of organs available for transplantation and is one of the potential benefits currently being explored [8].

With respect to kidney alone, there are two determining factors that delineate the clinical significance of kidney recovery, transport, preservation, and assessment techniques: first, the existing overwhelming demand/supply imbalance, and second, the substantial cost savings and quality of life improvements provided by a transplant versus chronic dialysis. Dialysis is currently the only other viable therapy for end-stage-renal disease (ESRD). By expanding the donor pool with “expanded criteria” and non-heart beating donors and improving the quality of heart-beating donor kidneys, the estimated increase in the number of transplantable kidneys is 40%, the improvement in reducing DGF is 35%, and the estimated annual savings to the U.S. healthcare system could be greater than \$1.5 billion.

More than 100,000 patients were registered for organ transplant on the UNOS waiting list by the end of February 2009, 78,565 of those being in need of a kidney transplant [150;151]. Three years earlier the number of kidney candidates on transplant waiting list was 66,961, 88% higher than in 1997. In 2006 there were 15,630 recovered kidneys with transplant potential, however only 76% were transplanted [150;151].

As summarized in the annual OPT/SRTR 2003 UNOS reports [27;28;39], the number of candidates on the kidney patient waiting list increased 6.3%, from 47,830 in 2001 to 50,855 in 2002. Seventy five percent of the increase occurred among patients of 50 years of age or older, these patients representing more than 50% of the total patients on the waiting list (compared to only 34% in 1993). Accordingly, the waiting time steadily increased from 235 days in 1993 to 341 in 2002. Kidney transplants from deceased donors increased from 7,500 in 1993 to 8,500 in 2002, and 15% of those were recovered from ECD. The use of ECD kidneys in older patients has become a common practice over the last decade, with recipients 50 years of age and older receiving 70% of these kidneys. The one-year kidney patient survival rate has been recorded at 94% and 97% for recipients of living and deceased organ donors, respectively.

Five years post transplantation the survival rate drops to 90.1% and 80.7% for the recipients of living and deceased organ donors, respectively.

The number of patients requiring kidney transplants has increased by 2,400 per year since 1998 [27;28] [39]. If 2,400 more kidneys, from 1,200 donors, either expanded criteria or NHB donors, had been procured each year, the waiting list would not have increased. Even today, the waiting list would not increase if each of the 59 organ procurement agencies in the U.S. obtained kidneys from two expanded criteria or NHB donors each month [30]. A program for procuring kidneys from NHB donors alone could result in a 40% increase in the overall supply of cadaveric kidneys. The literature indicates that there may be from two to four and a half times as many NHB donors as heart beating donors [82].

In an attempt to improve the availability of organs from NHBDs a classification of donors within this category has been adopted, and is often referred to as the Maastricht classification (Table 3). Four categories of NHBDs have been identified [83]. There is little experience with donors of Category I due to logistics and questions about the viability of the kidneys. Category II is the main source of NHB donors. This category includes patients with myocardial infarction and cerebral bleeding, as well as trauma victims. Category III comprises patients for whom life support has been withdrawn, as in a ventilator switch-off procedure. The 10 minutes no touch period is particularly relevant in Categories II and III. Category IV was introduced to remind doctors of the possibility of a switch to a non-heart-beating procedure when a heart beating procedure is complicated by an irreversible cardiac arrest.

There is an extensive literature on transplantation of kidneys from donors without heart-beats [64;147]. Kidneys from trauma donors without heart-beats survived as well as those from donors with heart-beats[25;26;52;82;⁸⁷;105;106;147;182]. Nearly half the recipients of kidneys from donors without heart-beats required dialysis during the first week after transplantation, and 4% of the kidneys in this group never functioned. Differences between the survival of kidneys from donors without heart-beats and the survival of those from donors with heart-beats were due entirely to graft failure in the first month after transplantation. This means that the disadvantage of using kidneys from donors without heart-beats could be reduced considerably, or eliminated if kidney viability measures were available to exclude poor kidneys, particularly those that will never function.

Use of kidneys from donors whose hearts have stopped beating could increase the supply of kidney transplants by a factor of 2 to 4.5[82]. Currently more than 99% of cadaveric kidneys available for transplantation come from hospitalized brain-dead donors whose hearts are still beating [151]. The acceptable warm ischemia time in a NHBD has not been determined. The precardiac arrest condition of the donor, as well as preexisting disease states and age are factors in determining organ quality. Although kidneys can withstand 30–45 minutes of cardiac arrest, the outcome of a kidney transplant is further complicated by recipient factors, such as state of immunization and cardiovascular status.

Clinical impact of Delayed Graft Function

The impact of delayed function on transplantation is negative, and is considered undesirable for both clinical and economic reasons. Delayed graft function is presently being addressed in several ways. The first and most common method is dialysis. The second is to adjust the patient's immunosuppression regime, e.g., by withholding cyclosporine. Schlumpf, *et al* [140] and Varty, *et al*. [177] replaced cyclosporine with antithymocyte globulin and OKT3, respectively, in order to avoid cyclosporine nephrotoxicity during the first days after transplantation. The third way of decreasing delayed function is machine preservation. There is a growing body of evidence that preservation by machine perfusion is advantageous for the preservation of ischemically damaged kidneys [74], and for improving immediate post-

transplant graft function [184]. Experiments have confirmed that machine perfusion preservation of kidneys damaged by warm ischemia is superior to preservation by simple cold storage. Machine perfusion has been reported to result in better survival rates and improved preservation of microcirculatory integrity [18;19].

The current resurgence of interest in the clinical use of HMP was marked by reports in the early 1990's that preservation by machine perfusion reduces delayed function rates and increases the rate of prompt function of renal grafts [11;59;84;110]. Moreover, machine perfusion with a modified ViaSpan® solution (Belzer's machine perfusate) has been found to be superior to machine perfusion with plasma-based perfusate [12]. Nevertheless, at that time the effect of machine perfusion on graft survival remained controversial [84;122]. Because machine perfusion preservation is relatively labor intensive, logistically demanding and costly, and because cold, static storage solutions are safe and effective, most transplant centers abandoned the use of preservation machines in the late 1980's in favor of the simpler static cold storage method. Nevertheless, machine perfusion was still shown to be preferable for prolonged preservation times [108], and for preservation of ischemically damaged kidneys. However, prolonged cold ischemia times may have to be avoided in NHBD kidneys since it may lead to further delayed function [29]. Cold ischemia time may also have a detrimental effect on graft survival in combination with delayed function, HLA-DR mismatch, and acute rejection [32]. In the case of organs already damaged by warm ischemia, as in NHBD kidneys, prolonged hypothermic ischemia may have an additional negative effect on transplant outcome, even if the kidneys are preserved by machine perfusion. Therefore, hypothermic preservation times for warm ischemic kidneys are currently being kept at a minimum. Furthermore, machine perfusion may even have benefits for heart beating donor kidneys, allowing both longer storage transport times, and better matching to more needy patients, and the promise of better short-term graft function.

Machine perfusion for preserving NHBD kidneys has been reported to result in better clinical performance when compared with simple cold storage in a study in which each machine perfused kidney was compared with its cold-stored contra-lateral control [105]. Furthermore, earlier reports of the excellent transplant results with NHBD kidneys were, at least, partially attributable to preservation by machine perfusion [34] [123]. Machine perfused kidneys from NHB donors show significantly higher early post-transplant delayed function rate when compared with matched machine perfused heart-beating donor grafts [35]. However, renal function recovers within six months post-transplantation, and both NHB and heart-beating donor kidneys have equal serum creatinine levels. On the other hand, NHB donor kidneys preserved by machine perfusion have less delayed function than NHB donor kidneys preserved by cold static storage [35].

More recently, at the Oxford Transplant Unit (UK) kidneys of Maastrich class III and IV of NHB donors were successfully perfused using the LifePort® Transporter (Organ Recovery Systems, Des Plaines, IL) [115]. For an average graft storage time of 13h and perfusion flow rate of 115.5 ± 7.8 mL/min, a 72.2% immediate renal function, and 28.8% delayed graft function without any graft loss in the postoperative period were noted [115]. In Russia only kidneys of Maastrich criteria II and IV of NHB donors are allowed to be used for organ donation [132;133]. Kidneys from uncontrolled NHB donors are of dubious quality due to significant exposure to warm ischemia that in turn causes major graft ischemia-reperfusion injuries and poor long term outcomes. To rescue those kidneys, the LifePort® Transporter was employed for their perfusion starting at the procurement site and at the time of organ recovery, in the operating room [132;133]. Systolic perfusion pressures of 30 mmHg and 40mmHg were used for 40–45min WIT, and 65min WIT kidneys, respectively [132]. Based on perfusion parameter selection, nine kidneys with extreme warm ischemia exposure of 59–65min were successfully transplanted. Moreover, it has been observed that for immediate-function grafts the decrease

in internal vascular resistance should take place within the first three hours of perfusion, whereas for delayed graft function organs, the reduction in the vascular resistance extends to the first 12 hours [132;133].

Machine perfusion, when compared to static storage, has been shown to be beneficial for ECD kidneys [128;129]. The length of patient hospital stay and DGF rate in recipients of ECD donor kidneys increase by 37% each when static storage of those kidneys was used. The incidence of graft function of ECD kidneys at six months post transplantation increases by 9% in the machine perfused kidneys relative to SCS kidneys. ECD kidneys with post transplantation DGF show 29% reduction in the flow rate during pumping, and 38.5% and 40.7% increase in the vascular resistance and perfusate calcium concentration, respectively [128;129].

In Poland, the analysis of the long-term results of 415 human renal transplants preserved either by machine perfusion using the MOX-100 Waters machine (Waters Instruments Inc., USA), or by simple cold storage revealed similar graft survival fifteen months post-transplantation between the two preservation methods (87.7% and 85%, respectively) [88]. Nevertheless, in spite of the significant difference in cold ischemia time between machine perfused and static stored kidneys (33.7 ± 7.6 h vs. 27.5 ± 7.4 h, $P < 0.05$, respectively) the incidence of return to hemodialysis treatment was significantly reduced in the machine preserved grafts (7.05%) in comparison to SCS kidneys (12.2%, $P < 0.05$). Five years post-transplantation, recipients of SCS kidneys returned to dialysis twice as frequently as recipients of perfused kidneys, and the 5 year graft survival of perfused kidneys was significantly better than that of cold stored organs (68.2% vs. 54.2%, $P < 0.05$, respectively) [88].

In summary, studies have shown that ECD kidneys preserved by SCS had an overall increased risk of reduced graft viability. However, HPP was clearly associated with a reduced incidence of delayed graft function, an overall improved graft survival, and an increased rate of clinical use [107;141;148]. Nevertheless, until recently these conclusions have remained equivocal due to the heterogeneity of existing clinical studies and especially the lack of prospective studies [174]. In recognition of the need for a controlled, prospective randomized study, Moers et al recently published the results of such a study involving 336 consecutive deceased donors from whom one kidney was randomly assigned to pulsatile perfusion and the contralateral kidney to SCS. One year follow-up showed that HMP reduced the risk of DGF and graft failure and improved graft survival in the first year after transplantation [112]. Moreover, a cost-effectiveness analysis in this study suggests that the additional costs of HMP are more than compensated by savings due to the reduced costs of graft function-related complications, especially of reduced need for continued or renewed dialysis in case of DGF, PNF, or graft failure [55].

HMP of other transplant organs (Heart, Liver and Pancreas)

Heart Preservation

It is widely documented that the safe cold ischemic time for clinical heart preservation is limited to 4–6 hours using principally SCS methods. However, it has been reported that continuously perfused hearts, at 8–10 °C for 5 hour, have post-volume loading cardiac indices comparable to the initial preischemic values, while the myocardium of static stored hearts, at 4 °C for 5 hour, is unable to reach its initial contractile properties. Hearts preserved using the two preservation techniques are biochemically and ultrastructurally similar [130]. Hypothermic perfusion facilitates early post-storage contractile capacity due to uniform myocardium cooling, constant washout of metabolic waste products during ischemia and continuous supplementation of the needed metabolic substances.

The resurgence of interest in the relative merits of HMP compared with SCS of other organs, notably the kidney, has led to new research studies focused on machine perfusion preservation of hearts in the past 5 years. Using a canine orthotopic transplant model, 6 months old mongrel dog hearts were transplanted after either 24 hours of continuous hypothermic perfusion at 5 °C and 15mmHg, or 4 hours of static storage at 4 °C [45]. Belzer-MP solution (KPS-1, Organ Recovery Systems, Des Plaines, Illinois) supplemented with hydroxyethyl starch, glutathione, adenine, and fructose-1,6-bisphosphate was used for perfusion preservation. A weight gain of 27.4% was recorded in the HMP hearts [45]. No significant differences were noticed between the static stored and machine perfused hearts in terms of the required duration of cardio-pulmonary bypass support, length of survival, degree of inotropic support and cardiac output. However, in comparison to static storage, continuous hypothermic perfusion provided optimal myocardial cooling (through the native coronary circulation), and continuous substrate supplementation with limited anaerobic metabolism while washing toxic by-products [45]. Machine perfusion is effective in reducing oxidative stress damage in the myocardium, since a significant increase in oxidative damage DNA by-product (8 oxoG) and a reduction in mismatch repair enzymes (MYH, OGG1 and MSH2) were seen in the static stored hearts relative to perfused hearts[46]. Additionally, machine perfusion offers a better preservation of the myocardial metabolism through reduced intracellular lactate and increased glucose production and higher intracellular high-energy phosphate [46].

Currently, no device for machine perfusion of human allograft hearts is FDA cleared for clinical use. Key parameters for optimum preservation such as perfusate composition and temperature, perfusion pressure and flow rate still need to be determined with myocardial edema being one of the highest risks of this technique. Nevertheless, several devices and techniques are currently under investigation. For example, The LifeCradle™ HR Cardiac Perfusion System of Organ Transport Systems Inc. (Frisco, TX) is specifically designed for hypothermic heart perfusion [31]. Supported by eight years of pre-clinical research and experience, the LifeCradle™ was originally scheduled for clinical trials to start in 2008 (www.allezoe.com/lifecradle.aspx). Another hypothermic perfusion heart transporter (Organ Recovery Systems Inc) has provided safe continuous hypothermic perfusion of dog hearts at set pressure for 24 hours as mentioned above [45;46].

The LifeCradle™ system was also used for dog heart perfusion with Celsior at 5 °C for 10h to study the influence of perfusate flow rate (5 to 30 mL/min/100 g) on myocardial flow distribution, myocardial metabolism and edema development during preservation [126]. For the majority of tested flow rates, the epicardial/endocardial perfusion ratio remained close to one. High myocardial flow resulted in low tissue lactate/alanine ratios, while hearts with low tissue flow were characterized by significant lactate accumulation or increase in lactate to alanine ratio in the myocardium. Low tissue flow organs had minimal myocardial weight gain over 10h ($11 \pm 4\%$) whereas hearts with high tissue flow experienced significant weight gain ($34 \pm 4\%$, $P < 0.01$) and high myocardial water content [126].

An alternative approach to machine preservation of donor hearts that relies upon normothermic perfusion instead of hypothermia has been investigated in recent years [31]. The Organ Care System (OCS, TransMedics) device perfuses the hearts with a warm, oxygenated, nutrient-rich blood while the organs are maintained beating [31]. The OCS has received the CE mark for European clinical use, while a clinical feasibility study was approved by FDA in US in April 2007 to evaluate the safety and performance of OCS for human heart preservation for transplantation (www.transmedics.com). At this time we are unaware of any reports of the results of the aforementioned planned clinical trials using any of these devices or techniques.

Liver Perfusion Preservation

Today, liver transplantation is an effective and preferred treatment of choice for patients with end-stage liver disease. Despite some early attempts to develop HMP techniques for liver preservation, clinical practice has relied upon SCS [15;101;127;144]. Nevertheless, due in part to the resurgence of interest in hypothermic perfusion preservation of kidneys as a means to increase the donor pool by facilitating the use of marginal donors, the prospects of HMP of livers has been revisited in recent years [70;72;73;97;175;176]. Three specific factors are identified as important for effective HMP, namely the type of perfusion solution, the characteristics of perfusion dynamics, and the need for oxygenation [175;176]. Van der Plaats et al have recently described a prototype device called the Groningen Machine Perfusion (GMP) system designed to deliver these presumed characteristics during 24h of continuous perfusion [56;176].

Currently, there is no hypothermic perfusion machine commercially available to be used to extend the present 4–6h limit of liver cold preservation for clinical transplantation. The technical performances of prototype machines such as the Groningen Liver Perfusion System (Netherlands) and the Organ Recovery Systems device were tested using porcine livers [113; 114;175;176]. Attention was given mainly to perfusion uniformity and cellular injury generation, hypothermia and flow regime maintenance, and consistency in oxygen supply during 24h continuous preservation. The Groningen hypothermic liver perfusion system contains an organ bath/solution reservoir, two centrifugal pumps, one pulsatile and one continuous, a hollow fiber membrane oxygenator, a battery pack and a measurement/control unit connected to a computer interface [176]. The pulsatile pump is used for hepatic artery perfusion and the continuous pump perfuses the portal vein without oxygenation, both pumps being constant pressure-controlled. Ice slush is used as the cooling source for perfusion temperature regulation between 5–7°C. Following 24h of perfusion, increased liver vascular resistance and hepatic edema was observed without endothelial cell or hepatocyte damage [176].

The Groningen Liver Perfusion system is under development by Organ Assist (Groningen, The Netherlands) [56]. Despite its compact design and portability, and excellent results so far in porcine liver transplantation, it has not yet been employed clinically. A second Dutch company, Doorzand (Amsterdam,) produces Airdrive, a user-friendly, disposable, compressed air powered perfusion device, successfully tested in preclinical trials [56]. In the first human clinical study involving 19 cases receiving HMP livers, carried out in 2008 at Columbia University, Guarrera's team reported that patient and graft survival were very good without episodes of primary non-function or vascular complications [56].

Monbaliu's group in Belgium has also reported recently on studies using a prototype machine (Organ Recovery Systems,) in which porcine livers were hypothermically perfused for 24h with Belzer-MPS at 4–6°C [113;114]. Pressure controlled continuous perfusion through both the hepatic artery (<25mmHg) and portal vein (<7mmHg) was applied. The pressure-controlled perfusion provided organ protection against sudden increase in perfusion pressure, thus reducing the risk of shear stress and damage to the sinusoidal endothelial cells [113]. Throughout perfusion higher vascular resistance was registered on the hepatic artery in comparison to the portal vein; the former decreased substantially during the first 6 hours of perfusion, while the latter remained almost constant. During preservation the perfusate aspartate amino transferase (AST) and LDH levels showed a slow small increase, in comparison to the liver fatty acid-binding protein (L-FABP), lactate and glucose that rose considerably in concentration by the end of perfusion relative to baseline [113]. In contrast to SCS where mean ATP levels are reduced in 24h of liver preservation by 47% relative to baseline, after 24h of HMP tissue ATP content increases to 166% when a low perfusion regime was applied (portal vein pressure and flow of 3–5 mmHg and 0.5 mL/g/min, respectively;

hepatic artery pressure of 20 mmHg)[178]. Under the latter conditions maintaining an oxygen tension of 310mmHg throughout perfusion brought the 24h ATP levels to 127% of baseline value. Livers perfused under low flow conditions with oxygenated solution preserved their appearance and morphology [178].

These recent studies investigating HMP of livers highlight the variability in machine preservation protocols and parameters studied, including the venous (0.14 to 0.5 mL/min/g) and arterial (0.1–1.2 mL/min/g) flows under both pulsatile and non-pulsatile settings [43; 179]. Seventy-two hour continuous hypothermic perfusion of pig livers through the portal vein only has also been reported. For dual perfusion low values of portal vein (3–4mmHg) and hepatic artery (20–30mmHg) pressures need to be used. Although both constant flow and constant pressure perfusion regimes can be employed, constant flow hypothermic perfusion for longer than 18h can damage sinusoidal endothelial cells and endoplasmic reticulum due to increased vascular resistance and shear stress [43]. Hypothermic oxygenated machine perfusion is a practical potential strategy for “marginal” liver preservation, where HMP preconditions the liver cells prior to the introduction of blood cells by reactivating mitochondrial respiration and oxidizing mitochondrial electron complexes prior to reperfusion. The reported preservation temperature ranges between 1 and 18 °C, with the suggestion that lower temperatures substantially increase the perfusate viscosity that in turn can damage the sinusoidal endothelial cell lining. Moreover, there remains a lack of consensus with regard to organ viability criteria. Vascular resistance along with perfusate aspartate amino transferase (AST) concentration, tissue ATP and liver fatty acid-binding protein (L-FABP) content are some of the preferred hepatic viability markers [179].

Pancreas Preservation

Earlier studies have demonstrated that pancreas hypothermic preservation by machine perfusion is feasible and can be safely extended to 24 and 48 hours [6;47;98;172;173]. Dedicated renal perfusion systems have been employed mostly [47;98;172;173] after appropriate modifications required to accommodate the physiologic low flow and pressure needs of the pancreas [6]. The latter helps avoid excessive organ edema that post-segmental transplantation and reperfusion has been documented to result in sub-capsular bleeding, hemorrhagic necrosis, venous congestion, and hemorrhagic pancreaticoduodenal secretions [172]. The special case of pancreas preservation prior to islet isolation as a prelude to the treatment of Type I diabetes by islet transplantation is discussed in the “Future Applications” section below.

Future Applications and Current Research

An increasing number of OPOs and transplant centers around the world are adopting HMP of kidneys as the preservation modality of choice in an attempt to close the ever widening gap between supply and demand by relying increasingly upon ECD kidneys or marginal donor organs. Moreover, the multifaceted advantages of HMP over conventional SCS, summarized in Table 2, have resulted in a resurgence of interest for preservation of other organs besides the kidney. The opportunity to improve the assessment of the quality of the organ during perfusion preservation in an attempt to reduce the discard rate for transplantation is a very important prospect that deserves more attention and research.

Assessment of the quality of donor organs during HMP

As discussed in the previous sections, machine perfusion improves immediate post-transplant graft function, provides better survival rates and enhanced preservation of microcirculatory integrity [18;19]. Hypothermic machine perfusion allows for extended storage and transport times and for the possibility of kidney performance assessment and metabolic support provision

during perfusion [35;146]. Presently, during machine perfusion, renal flow rate and vascular resistance are the only accepted indicators of kidney *in-vitro* viability [86;104;128]. A small number of biochemical parameters and ischemic injury markers have been quantified in the renal effluent [79;80;128;129], yet their use is limited, and their role in predicting kidney *in-vivo* function and transplant outcome is still controversial. Thus, the need for a complete and diagnostically valuable evaluation of kidney function *ex-vivo* still remains.

Machine perfusion based viability testing can be successfully used to select good quality kidneys for transplantation [85;103;116]. The Newcastle (UK) clinical viability protocol for hypothermically machine perfused kidneys from NHB donors requires perfusion flow indices of 0.4 ml/min/100g/mmHg or greater, and perfusate GST content of less than 100 IU/L/100g renal mass [116]. In Japan, another perfusion apparatus, LPS-II (Nikiso, Tokyo, Japan), that consists of a non-pulsatile pump, heat exchanger, organ chamber, reservoirs and a membrane oxygenator has been used for cadaveric kidney perfusion preservation. Those kidneys, which showed perfusion flow rates of at least 0.4 ml/min/g and no increase in the perfusion pressure during machine preservation, were selected for transplantation [103]. Due to unavailability of Belzer-MPS in Japan, kidneys are normally perfused with cryoprecipitated AB positive plasma at a temperature of 8–10°C and an average perfusion pressure of 30–50 mmHg for 8–12 hours [103]. Kidneys displaying 0.40–0.65 ml/min/g perfusion flows have a 25.7% incidence of PNF in comparison to kidneys of 0.90 ml/min/g flow rates [103]. From the LPS-II renal perfusion apparatus organs showing 1.10 mL/min/g flow rate and 55.3 mmHg/mL/min/g vascular resistance were successfully transplanted, without any incidence of DGF post reperfusion [85].

Identifying and developing improved methods to evaluate kidney quality (viability) during hypothermic preservation have been the objectives of many studies. A five-channel sensor used to measure temperature and ion activities (K^+ , Na^+ , Ca^{++} , pH) in the intersitium of human kidneys [2] detected significantly higher potassium activity in nonfunctioning kidneys when compared to primary functioning grafts (18 versus 3.9 mmol/L). Changes in the glomerular dynamics (evaluated using the ureteral output), and increased renal vascular resistance at the postglomerular level during hypothermic machine perfusion were linked to a decline in the renal perfusate flow rate [124]. The viability of machine preserved NHB donor kidneys was determined by calculating the intrarenal resistance and determining lactate dehydrogenase and α -glutathione S-transferase (α GST) concentrations [36;79]. The latter correlated well with warm ischemia damage, high levels of α GST predicting poorer post transplant graft function or even non-function. The proximal tubule lysosomal enzyme glutathione S-transferase is the best predictor of outcome of human kidney function before transplantation because of the correlation between warm ischemia time and the release of proximal tubule cell enzyme α GST in the machine perfusate. However, while high α GST is a predictor of poor outcome, low α GST does not necessarily indicate a good perfusion result [80].

The efficacy of hypothermic pulsatile perfusion for ischemically damaged human kidneys was established by measuring perfusion parameters, perfusate electrolytes, perfusate gas values and kidney ischemic injury markers [37]. Perfusate Na^+ , K^+ , pH and osmolarity showed no variation between delayed function and immediate function grafts, while flow was significantly elevated in the immediate functioning group and lactate dehydrogenase index was higher in the delayed function graft (16.48 ± 1.3 vs 9.95 ± 2.3) [37]. Using NHB donor canine kidneys, it was shown [62] that machine perfusion with trifluoperazine added to Belzer-MPS improves kidney function by reversing the vasospastic effects of ischemia and reperfusion. However, after implantation and 4 hours of reperfusion, machine perfused NHB donor kidneys showed significantly higher Na^+/K^+ ratios (6.61 vs 2.16) and creatinine clearance levels when compared to heart-beating donor derived kidneys [62].

The development of reliable methods for organ viability assessment is important to the reduction of delayed graft function rate in the recipients of NHB donor kidneys. Two criteria for *in-vitro* quality control of kidneys have been developed [86;104]: (1) perfusion flow rates higher than 0.4 mL/min/g with increasing flow during perfusion, and (2) no increase or reduction in renal arterial pressure over time. The addition of prostaglandin E1 (PGE1) to machine perfusate improves kidney function by ameliorating mitochondrial ischemic injury (seen in EM images) and reducing release of Ca^{++} into the perfusate [128;129]. Quantitative hydrostatic and biochemical criteria were used to evaluate kidney function and to select well perfused kidneys for transplantation: renal flow rate higher than 0.5 mL/(min g), flow resistance smaller than 0.0085 (mmHg min)/(mL g) and perfusate Ca^{++} less than 0.002mM/g [128]. Kidneys with a mean flow rate of 1.56 mL/(min g) and vascular resistance of 0.0027 (mmHg min)/(mL g) showed no delayed function after transplantation. Increased ionized Ca^{++} concentration in ischemic damaged kidneys effluent reflects disruption of the structural integrity of cellular organelles with subsequent lysis and release of intracellular calcium.

In recent years we have addressed the question of *ex vivo* organ viability assessment in our own program of research to investigate kidney preservation technologies with the ultimate goal of reducing the current renal discard rate and improving the use of marginal donor kidneys. As part of this program we have begun to study the role of the perfusate in modulating kidney biochemical perturbations during lengthy machine perfusion, and to emphasize that a comprehensive assessment of kidneys *ex-vivo* performance is needed for a reliable screening of viable organs for transplantation. A more complete assessment of viability has to consider renal biochemistry in addition to the traditional biophysical parameters of flow rate and vascular resistance, but apart from the few studies summarized above there have been very few studies taking this additional approach [37]. For example, we recently reported on the role of the perfusate in modulating biochemical perturbations during extended machine preservation of kidneys [10]. For this study, we compared the kidney effluent composition during 72h HMP with either Belzer's MPS, or the new Unisol™-UHK proprietary hypothermic blood substitute solution [157;160;170]. Unisol is designed, among other characteristics, to have a higher buffering capacity than the commonly used preservation solutions [7], and provides superior protection of the vascular endothelium [171], as well as optimum buffer capacity for acid-base regulation during prolonged HMP of kidneys [9]. Unisol™-UHK is an intracellular base solution designed for applications at profound hypothermic temperatures (<15 °C) [7;157; 158;160;169]. Belzer's-MPS is the current clinical standard for machine perfusion of kidneys [128;152]. Kidney perfusion flow parameters, with similar values between the two experimental groups, satisfied the published acceptance criteria for transplantation [86;104; 128;152]. Thus, from a renal flow point of view, the two perfusates, UHK and Belzer-MPS were equivalent. However, marked differences were monitored between the two experimental groups in terms of kidney biochemical and metabolic activity as determined by effluent perfusate analysis [10]. These data serve to emphasize that a comprehensive assessment of kidney *ex-vivo* function during the preservation interval would facilitate a greater degree of discrimination, and allow for a more accurate and reliable selection of viable kidneys for transplantation. Nevertheless, analysis of the effluent perfusate from the perfused organ is not the only approach for improved assessment of the organ status during perfusion preservation. Recently we have advocated the use of interstitial fluid analysis using microdialysis as a potentially new approach for assessing organ function during perfusion preservation [8].

Microdialysis for organ assessment during HMP—Microdialysis is used as a bio-analytical sampling technique to monitor the chemistry of the extracellular space in living tissues without altering the fluid balance or the metabolic pathways. Information on the relative concentration of tissue interstitial fluid components can be obtained every few minutes, over long periods of time, without loss of blood or other fluids, with minimal dilution by blood and negligible metabolite breakdown. Microdialysis consists of implanting a very small dialysis

probe into the examined tissue. The probe is analogous to a blood capillary vessel, with a semi-permeable bio-compatible membrane as the active part that, based on its pore size, permits only specific molecular weight components of the extracellular space to pass through. The working principle of microdialysis consists of forcing an isotonic fluid through the probe inlet port into the probe membrane, at a low, constant and controllable flow rate, in order to allow the isotonic fluid equilibration with the interstitial fluid, and collection of the dialysate at the outlet probe port. The isotonic fluid, with an identical ionic composition, physiologically resembles the targeted interstitial fluid.

The use of microdialysis has increased dramatically in recent years for a wide variety of research investigations and clinical studies [60;92;183]. For example, microdialysis has been used to measure renal interstitial adenosine concentration and its role in the regulation of renal hemodynamics during endotoxin shock and induction of acute renal failure [119]. Also, it has been proven using microdialysis that renal cortical interstitium contains detectable amounts of ATP that consistently decrease in response to reduction of the renal arterial pressure, in correlation with the autoregulation-associated alteration in renal vascular resistance [118]. Clinically, the microdialysis method applications cover a broad spectrum, that includes, among others, vascular and plastic surgery, hemodialysis, neuromonitoring in neurointensive care, neonatal investigations, diabetes, metabolism, and intra-dermal and intra-abdominal studies.

In the field of organ preservation and transplantation the microdialysis technique has been used to continuously monitor the metabolic changes in a porcine liver graft during transplantation. A microdialysis catheter of 20kDa membrane cutoff was inserted into the liver and perfused at 0.3 $\mu\text{L}/\text{min}$ with sterile isotonic solution. Microdialysates were collected at 20 minute intervals during the donor operation, during 15 hour of static cold preservation, and for 7 hours post-transplantation. One single microdialysis probe measured simultaneously four metabolite concentrations, glucose, lactate, pyruvate and glycerol. The method proved to be a useful tool in estimating liver graft tissue injury due to cold ischemia and transplantation, through intrahepatic biochemistry [120]. Nevertheless, based on an extensive literature survey, no research or clinical studies of kidney preservation have employed the microdialysis technique to monitor renal extracellular space electrolytes and metabolites during either *ex-vivo* organ perfusion or SCS. Implementation of this method is expected to bring accuracy in monitoring renal biochemical activity of hypothermically preserved kidneys. The microdialysis probe would be placed in intimate contact with the tissue, allowing the interstitial fluid components to be collected from the immediate vicinity of their production location. Consequently, the loss in their concentration, due to transport across the extracellular space into the blood vessels, and dilution in the perfusion/preservation solution would be avoided. Furthermore, the opportunity for cell products to be degraded prior to collection would be minimized.

Experimental study in porcine kidneys: To put this to the test an experimental study was performed in our laboratory to evaluate the merits of the microdialysis method in terms of its practicality for renal viability assessment, suitability and simplicity for monitoring biochemical activity of kidneys through the collection and analysis of renal interstitial fluid, during hypothermic preservation [8]. For this, porcine kidneys recovered from 2 hour-warm-ischemic-NHB donors were hypothermically machine perfused for 24 hour, at 5–7 °C and 30–60 mmHg arterial pressure, using the continuous pulsatile perfusion prototype of the LifePort® kidney preservation system. The kidneys were perfused with Belzer-MPS. Renal interstitial fluid was periodically sampled using flexible peripheral tissue-type microdialysis probes of 20kDa molecular cut-off and 10 mm membrane length (CMA/20, CMA Microdialysis, Sweden). As illustrated in Fig 3, a single microdialysis probe was inserted into the renal cortex (pole) of each kidney and interstitial fluid samples were collected hourly while the kidneys were perfused. The probes were perfused with isotonic fluid at a flow rate of 2.5 $\mu\text{L}/\text{min}$, and the dialysates were collected in vials placed in a 4 °C refrigerated fraction collector. Renal effluent

samples were collected in parallel with the microdialysates. Both renal effluent samples and microdialysates were analyzed for pyruvate concentrations, pyruvate being one of the important metabolic activity indicators. More specifically, this pilot study included an investigation of the effect of the addition of fructose-1,6-diphosphate (FDP) as an energy substrate to promote anaerobic glycolysis in the hypoxic perfused kidneys [8]. The rationale for this approach was based upon the premise that during glycolysis the eventual pathway block by the build up of lactate, which in turn inhibits phosphofructokinase (PFK), can be circumvented by the supply of exogenous FDP [95;154;155].

The presence of exogenous FDP in the perfusate induced no changes in the renal flow rate and vascular resistance, renal effluent biochemistry, or pyruvate concentration relative to untreated control kidneys. Significant increases in pyruvate production ($P < 0.05$), however, were observed after 12 h of perfusion in the interstitial fluid of FDP-treated kidneys relative to control kidneys (Fig 3b). After 24 h of perfusion, interstitial fluid concentrations of pyruvate were 149.1 ± 58.4 vs. $55.6 \pm 17.9 \mu\text{M}$ ($P < 0.05$) in the FDP and control group, respectively. The microdialysis probe collected the interstitial fluid directly from the cellular sites of metabolic and synthetic activity, where perfusate dilution was minimal. Consequently, the biochemical changes induced by the organ metabolic activity were detected only at the interstitial level, in the microdialysates. Interstitial fluid pyruvate may be a good indicator of kidney function. The addition of FDP to the perfusion solution during ischaemic kidney preservation resulted in enhanced pyruvate production in the extracellular space, indirectly reflecting an increase in anaerobic ATP production. The pyruvate will be transformed during organ reperfusion into acetyl Co-A enzyme allowing an immediate start of aerobic metabolism. This in turn can increase the amount of ATP available to the cells and may help prevent reperfusion injury upon transplantation.

This study illustrates that microdialysis is effective in monitoring biochemical changes in the organ that were not detected by analyzing the - perfusate. We propose that the interstitial biochemical profiles might be a better indicator of kidney viability, enabling more effective, valid decisions to be made on suitability of NHB donor derived kidneys for transplantation.

Pancreas HMP for Islet Isolation

There is now a worldwide consensus that islet transplantation may be considered a viable option for the treatment of insulin-dependent diabetes mellitus, and clinical trials are underway at many centers around the world [5;142]. As this approach for curing diabetes transitions into a routine clinical standard of care so the demand for donor islets will escalate. Moreover, the potential for xenotransplantation to relieve the demand on an inadequate supply of human pancreases will also be dependent upon the efficiency of techniques for isolating islets from the source pancreases. Procurement of donor pancreases for islet isolation and transplantation is not yet widely practiced due in part to concerns about post-mortem ischemia upon functional islet yields [89].

Islets are highly vulnerable to irreversible damage after prolonged ischemia [16;22;23;41;42;153], and cold ischemia of the cadaveric pancreas is detrimental to islet yield [17;53;61;78;89;136]. In vitro studies have shown a significant reduction in insulin release in response to glucose challenge even after short periods of cold storage in UW solution [53]. These observations have been seen in clinical practice as there have been no reports of successful single-donor islet transplants with prolonged cold storage beyond 10 hours [61]. Ryan et al have provided evidence of the detrimental impact of cold ischemia on post-transplant islet function [137].

Transplanted islets isolated from 24 hour perfused dog pancreata have been reported to result in 60% recipient survival post transplantation, providing similar outcome to fresh islet

implantation [173]. Islets isolated from human pancreas after 13 hour of SCS and 4 hours of hypothermic pulsatile perfusion on a Waters RM3 system were characterized by higher viable yield and stimulation index relative to cells isolated from organs that sustained more than 8 hours of static storage alone [98]. Against this background, our studies have been designed to test the general hypothesis that, in line with our experience with clinical kidney preservation, machine perfusion will facilitate improved pancreas preservation. Moreover, it is anticipated that this will extend beyond the present clinical limit of 16 hours for conventional cold storage and will improve the yield and potency of islets isolated from marginal donor pancreases that may suffer a period of warm ischemia in addition to prolonged cold storage. Since HPP technology has had a major impact on circumventing ischemic injury in kidney transplantation [35;84;110], we applied this approach to the preservation and procurement of viable islets after HMP of porcine pancreata since pigs are now considered the donor species of choice for xenogeneic islet transplantation for a number of compelling reasons [121].

Experimental study in porcine pancreas

In light of the brief history of pancreas perfusion preservation outlined above, and current resurgence of clinical interest in HMP of donor organs, we embarked upon the development of a perfusion technique for pancreas preservation prior to islet isolation [161;163]. Considerable attention to detail was necessary in the development of a successful technique for perfusion of pig pancreata on the LifePort perfusion machine. Both the surgical dissection, including the mode of cannulation, and configuration in the organ cassette on the machine proved to be important in the development of a technique that guaranteed 24h continuous perfusion [161;164] (Fig 4). The LifePort perfusion machine provided a controlled closed loop pulsatile perfusion at a set systolic pressure of 10mm Hg (Fig 5)[166].

These studies revealed an unexpected salutary effect of machine perfusion on islet harvesting. The progressive development of edema during extended machine perfusion of organs is a phenomenon that is generally regarded as undesirable. Steps are usually taken to minimize the problem by adjusting the mechanical perfusion parameters such as flow and pressure, as well as the composition of the perfusate, to minimize the development of interstitial edema. Having resolved a technical problem with respect to cannulation of the pancreas that affects the efficiency of perfusion as described elsewhere [161;164], we determined that 24h of HMP resulted in moderate edema in the gland compared to the non-perfused controls that were simply flushed with and immersed in cold UW/Viaspan solution. Contrary to expectations, development of edema (up to 150%) did not prove deleterious, but was shown to be of considerable benefit by correlating with a more efficient disruption of the pancreas during enzymatic digestion to yield a significantly greater number of islets (Fig 6). In fact, the increased yield over the fresh group of pancreases was 1.6–1.8 times greater and approximately 2–3-fold greater than for pancreases preserved by SCS in UW/Viaspan. Our hypothesis is that the edema causes sufficient disruption to the extracellular matrix and architecture of the pancreatic gland that the subsequent distension and digestion of the gland was able to proceed more effectively. This is evidenced by shorter digestion times, a more homogeneous digestion product, and better gradient purification resulting in higher yields and purity of the final islet preparation. The structure and function of the islets *per se* did not appear to be compromised by the level of tissue edema encountered in these studies [162–164]. Concerns that a change in the hydration of the isolated islets due to HMP might alter the buoyant density of the islets, and thereby critically alter their ability to be separated from exocrine tissue on a density gradient did not appear to be a problem. This is presumably due to the fact that any inherent edema in the islets is counteracted by the pre-gradient incubation in UW solution, which is a hypertonic medium that would dehydrate the islets during the 30min cold incubation prior to loading on the density gradient for purification. The latter is a routine step used in islet isolation protocols [90;91].

The unanticipated mechanical benefit of HMP described above was achieved without compromising the quality of the isolated islets (Table 4). The functional ability, in terms of their insulin-secretory index, of the islets isolated from the perfused pancreases was equivalent to that of the controls including fresh pancreas. Moreover, the insulin content was significantly higher than the control group comprising pancreases stored statically in cold UW/Viaspan solution, which is currently the standard method employed clinically. It was further demonstrated that these effects and standards of preservation were achieved irrespective of the nature of the perfusate since equivalence was demonstrated using the two proprietary solutions, KPS1 and Unisol-UHK[164]. Further improvements and benefits to this technique are anticipated by optimizing the composition of these baseline perfusates by adding cytoprotective agents designed to minimize preservation and reperfusion injury [158].

If this unanticipated finding is validated in further studies designed to evaluate the in vivo function of the islets, the implication would be very significant for the field of islet transplantation. Despite many efforts to improve the technique of islet isolation the field remains constrained by the limitations and vagaries of enzymatic digestion of a gland that comprises less than 5% endocrine tissue. Consequently, isolating islets from a single donor pancreas often yields insufficient islet mass to reverse diabetes in a recipient, such that multiple donors often have to be considered for treating a single recipient. Our initial results using HMP strongly suggest that the development of a moderate degree of interstitial edema while preserving the integrity of the islets greatly facilitates islet isolation to the extent that approximately twice as many islets may be retrieved compared with non-perfused pancreases. Moreover, the salutary effects of HMP were also manifest after prior warm ischemia [162-164].

The role of oxygenation during HMP

Although tissue energy requirements are minimal at deep hypothermic temperatures, there are suggestions that constant supply of oxygen along with adenosine as a precursor for the replenishment of ATP will result in superior ATP levels[44;81;93;102;127;145], and minimum oxidative and metabolic stress in preserved tissues. However, there is no clear consensus among the research community about the need of oxygen supply during hypothermia. There are concerns that low concentrations of molecular oxygen, such as that dissolved in organ preservation solutions, is sufficient to support the generation of free radicals during prolonged storage [50;125]. It is recognized therefore, that hypothermia may set the stage for a progressive development of tissue injury as a result of reactions and processes that occur during hypothermia, but that fuel changes that proceed for considerable time after normal conditions of temperature and oxygen tension are resumed. Others have shown that a moderated oxygen tension is beneficial during hypothermic preservation, which suggest that oxidative stress can lead to adaptation in tissues and increased production of antioxidants. It has been shown that rats gradually exposed to oxygen increased their production of pulmonary antioxidants [58]. Nevertheless, numerous investigations have suggested that oxygen supply is essential during hypothermic preservation of livers [94;111;175]. Recent studies on transplantation survival [97] of rat livers from NHBDs suggest that the saturation of UW solution with atmospheric air is a primary requirement for the preservation and restoration of ATP levels and mitochondrial functions [96]. Previous studies by Stubentisky et al have also shown that the oxygenated hypothermic preservation of warm ischemic kidney slices can restore normal tissue ATP levels [149]. In respect of oxygenation of perfused livers it has recently been determined that a partial pressure of oxygen equal to 55 kPa is needed to comply with total liver oxygen demand during HMP [1;48]. Since physiological distribution of oxygen in the liver is supplied via both the hepatic artery (65%) and portal vein (35%), a pO₂ of 35.8kPa and 19.2kPa has been set by some investigators as the target supply levels in these respective lines during HMP [176].

Studies that clearly demonstrate the rapid depletion of adenine nucleotides during cold storage of organs at 0–2°C are suggestive that mitochondrial function is severely impaired by hypothermia [21]. However it has been demonstrated, for example in the liver that the same tissues stored at 8 – 10° C can reestablish ATP reserves if an adequate supply of oxygen is maintained by continuous perfusion as discussed above [49;96]. Moreover, it has also been established during hypothermic kidney preservation that the balance between glycolysis and complete oxidation of fatty acids at 10°C is controlled by the oxygen tension. Pegg et al showed that glycolysis provided the principal source of energy at 10°C when the pO₂ =150 mm Hg, but that oxidation of caprylic acid provided the main fuel when pO₂ was raised to 650 mm Hg [125]. Furthermore, it had previously been demonstrated by Huang et al using well oxygenated kidney cortex slices that the preferred substrate for energy metabolism was also markedly influenced by temperature. Under normothermic conditions glucose, amino acids, ketone bodies and fatty acids were all utilized, but only short chain fatty acids and ketone bodies were consumed at 10°C [63]. Clearly the effect of cooling on metabolism is complex, and should not be regarded as causing a simple uniform retardation of all biochemical reactions [158]. More investigation is required to arrive at a consensus on optimum oxygen tension requirement that can provide superior graft function and prevent oxidative damage.

Multiple organ perfusion *in situ* and the special case of whole-body perfusion

It will be obvious from the forgoing discussion and other recent reviews on this topic [51; 57], that the technology of HPP has focused on individual transplantable organs. However, it should be recognized that organ preservation should start at the earliest possible onset of ischemia, i.e. in the donor. Optimizing organ procurement techniques will inevitably help to improve the health of the organ after preservation. To this end, some researchers have recently advocated “in situ” machine perfusion of multiple organs to facilitate the wash-out and cooling of all organs at the same time as providing better metabolic support to reduce the mismatch between metabolic demand and supply [169;176]. The basis for this concept is the well established techniques of extracorporeal bypass perfusion used extensively in some clinical settings, notably cardiovascular surgery [54].

Special Case of Whole-body Hypothermic Perfusion

Historically, a variety of organ preservation solutions have been developed, and while there are accepted industry standards for certain organs and applications, the concept of a “Universal” preservation solution for all tissues and organs has still to be realized in practice. In general, the solutions adopted for abdominal visceral organs (kidney, liver and pancreas) have not proved optimal for thoracic organs (heart and lungs), and vice versa. In contrast, a new approach to bloodless surgery using hypothermic blood substitution (HBS) to protect the whole body during profound hypothermic circulatory arrest (clinical suspended animation, or “*corporoplegia*” - literally meaning body paralysis [160;167]) has focused on the development of a hybrid solution design with the objective of providing “universal” tissue preservation during whole-body hypothermic vascular flushing [158;160;165;168].

We have investigated this approach based upon the “Unisol” concept [157], in which two new solutions (a *Maintenance* and a *Purge*) formulated for separate roles in the procedure have been tested [4;171]. The principal solution is a hyperkalemic, “intracellular-type” solution designed to “maintain” cellular integrity during hypothermic exposure at the nadir temperature (<10°C). The companion solution is an “extracellular-type” purge solution designed to interface between blood and the *Maintenance* solution during both cooling and warming. This novel approach to clinical suspended animation has been established in several large animal models [160;165;168], and more recently explored for resuscitation after traumatic hemorrhagic shock in pre-clinical models relevant to both civilian and military applications [4;13;14;134;160].

In considering the efficacy of a solution for universal tissue preservation there is no better test than to expose all the tissues of the body to cold ischemia. Moreover, protection of those tissues most exquisitely sensitive to an ischemia/hypoxia insult, namely the heart and brain, provides the greatest challenge. Current interests in the development of hypothermic arrest techniques to facilitate resuscitation of hemorrhagic shock victims in trauma medicine has parenthetically provided an opportunity to examine the efficacy of new hypothermic blood substitution solutions for universal tissue preservation during multi-organ perfusion[160;165;168].

Successful application of a technique of hypothermic blood substitution to man would provide a > 3-fold extension of the current limits of <1 hour for “safe” arrest without a high risk of neurological complications. This novel approach to bloodless surgery would significantly broaden the window of opportunity for surgical intervention in a variety of currently inoperable cases, principally in the areas of cardiovascular surgery, neurosurgery and emergency trauma surgery. This provides further evidence for the protective properties of solutions such as the Unisol family of solutions used for global tissue preservation during whole body perfusion in which the microvasculature of the heart and brain are especially vulnerable to ischemic injury [69;168]. Moreover, the application of solution-design for clinical suspended animation and Emergency Preservation and Resuscitation (EPR) under conditions of ultraprofound hypothermia, places HBS solutions such as Hypothermosol® (Biolife Solutions, Inc.[156]) and Unisol® (Organ Recovery Systems, Inc.[157]) in a unique category as universal preservation media for all tissues in the body. In contrast, all other organ preservation media, including the most widely used commercial solutions such as UW - Viaspan® (SPS-1, Organ Recovery Systems,) are established for specific organs, or groups of organs, e.g. UW for abdominal organs and Celsior, Cardiosol, or Custodiol for thoracic organs [7;40]. Moreover, the demonstrated efficacy of these synthetic, acellular hypothermic blood substitute solutions justifies their consideration for multiple organ harvesting from cadaveric and heart-beating donors [169].

Future Directions

Hypothermic machine perfusion preservation technologies have been explored more extensively in recent years because of the contributory role they play in narrowing the gap between supply and demand of organs for transplantation. While current HPP techniques are being successfully exploited clinically, defined areas for improvement are recognized for future developments. Focus upon organ specific metabolic demands (oxygenation and perfusate components) and circulatory requirements (optimized flow regime, infusion flow rate and pressure) at low temperatures is necessary. These will help extend the current short preservation time limits for liver, heart and pancreas, and thus, provide the time for proper donor-recipient matching and the distribution of organ to the best matched recipient. Moreover improving evaluation methods for the condition of an organ and quality control during hypothermic perfusion by developing and establishing biomarkers and other indices of organ function and viability (currently only flow rate and vascular resistance are recognized as renal viability indicators) will help expand the donor pool (warm ischemia damaged organs), eliminate poor quality organs from transplantation, and allow for the selection of organs with low rate of post-transplant complications.

Acknowledgments

We gratefully acknowledge the assistance of Ms. Elizabeth Greene with the preparation of the figures for this article. Our own research reported herein relating to pancreas perfusion preservation was supported in part by grants from the NIH (R44DK065508 and R44DK076326).

Abbreviations

DGF	Delayed graft function
PNF	Primary non-function
ECD	Expanded Criteria Donor
NHBD	Non-heartbeating donor
DCD	Donation after Cardiac Death

Reference List

- [1]. 't Hart NA, van der Plaats A, Moers C, Leuvenink HG, Wiersema-Buist J, Verkerke GJ, Rakhorst G, Ploeg RJ. Development of the isolated dual perfused rat liver model as an improved reperfusion model for transplantation research. *Int J.Artif.Organs* 2006;29:219–227. [PubMed: 16552669]
- [2]. Abendroth D, Schilling M, Fenzlein PG, Land W. Pretransplant assessment of renal viability by using ion-selective electrodes—a pilot study. *Transplant Proc* 1993;25:2563–2564. [PubMed: 8356670]
- [3]. Abouna, GM. Perfusion Technology. In: Karow, A.; Abouna, GM.; Humphries, AL., editors. *Organ Preservation for Transplantation*. Little Brown; Boston: 1974. p. 239-258.
- [4]. Alam HB, Bowyer MW, Koustova E, Gushchin V, Anderson D, Stanton K, Kreishman P, Cryer CMT, Hancock T, Rhee P. Learning and memory is preserved after induced asanguineous hyperkalemic hypothermic arrest in a swine model of traumatic exsanguination. *Surgery* 2002;132:278–288. [PubMed: 12219024]
- [5]. Alejandro R, Barton FB, Hering BJ, Wease S. 2008 Update from the Collaborative Islet Transplant Registry. *Transplantation* 2008;86:1783–1788. [PubMed: 19104422]
- [6]. Alteveer RJ, Jaffe MJ, Van Dam J. Hemodynamics and metabolism of the in vivo vascularly isolated canine pancreas. *Am.J.Physiol* 1979;236:E626–E632. [PubMed: 443418]
- [7]. Baicu S, Taylor MJ. Acid-base buffering in organ preservation solutions as a function of temperature: New parameters for comparing buffer capacity and efficiency. *Cryobiology* 2002;45:33–48. [PubMed: 12445548]
- [8]. Baicu SC, Simmons PM, Campbell LH, Taylor MJ, Brockbank KG. Interstitial fluid analysis for assessment of organ function. *Clin.Transplant* 2004;18(Suppl 12):16–21. [PubMed: 15217402]
- [9]. Baicu SC, Taylor MJ, Brockbank KG. The role of preservation solution on acid-base regulation during machine perfusion of kidneys. *Clin.Transplant* 2006;20:113–121. [PubMed: 16556165]
- [10]. Baicu SC, Taylor MJ, Brockbank KG. Modulating biochemical perturbations during 72-hour machine perfusion of kidneys: role of preservation solution. *Cryobiology* 2007;54:114–120. [PubMed: 17196191]
- [11]. Barber WH, Deierhoi MH, Phillips MG, Diethelm AG. Preservation by pulsatile perfusion improves early renal allograft function. *Transplant Proc* 1988;20:865–868. [PubMed: 3055519]
- [12]. Barber WH, Laskow DA, Deierhoi MH, Poplawski SC, Diethelm AG. Comparison of simple hypothermic storage, pulsatile perfusion with Belzer's gluconate-albumin solution, and pulsatile perfusion with UW solution for renal allografts preservation. *Transplant Proc* 1991;23:2394–2395. [PubMed: 1926399]
- [13]. Behringer W, Safar P, Kentner R, Wu X, Radovsky A, Tisherman SA, Taylor MJ. Novel solutions for intra-ischemic aortic cold flush for preservation during 30 min cardiac arrest in dogs. *Crit Care Med* 2001;29:226.
- [14]. Behringer W, Safar P, Nozari A, Wu X, Kentner R, Tisherman SA, Radovsky A, Taylor MJ. Intact survival of 120 min cardiac arrest at 10°C in dogs. Cerebral preservation by cold aortic flush (and novel solutions). *Crit Care Med* 2001;29:225.
- [15]. Belzer FO, May R, Berry MN, Lee JC. Short term preservation of porcine livers. *J.Surg.Res* 1970;10:55–61. [PubMed: 4903366]
- [16]. Belzer FO, Ploeg RJ, Knechtle SJ, D'Alessandro AM, Pirsch JD, Kalayoglu MM, Sollinger HW. Clinical pancreas preservation and transplantation. *Transplant.Proc* 1994;26:550–551. [PubMed: 8171549]

- [17]. Benhamou PY, Watt PC, Mullen Y, Ingles S, Watanabe Y, Nomura Y, Hober C, Miyamoto M, Kenmochi T, Passaro EP. Human islet isolation in 104 consecutive cases. Factors affecting isolation success. *Transplantation* 1994;57:1804–1810. [PubMed: 8016887]
- [18]. Booster MH, Wijnen RMH, Yin M, Tiebosch ATM, Heineman E, Maessen JG, Buurman WA, Kurvers HAJM, Stubenitsky BM, Bonke H, Kootstra G. Enhanced resistance to the effects of normothermic ischemia in kidneys using pulsatile machine perfusion. *Transplant Proc* 1993;25:3006–3011. [PubMed: 8266432]
- [19]. Booster MH, Yin M, Stubenitsky BM, Kemerink GJ, van Kroonenburgh MJPG, Heidendal GAK, Halders SGEA, Heineman E, Buurman WA, Wijnen RM, Tiebosch ATM, Bonke H. Beneficial effect of machine perfusion on the preservation of renal microcirculatory integrity in ischemically damaged kidney. *Transplant Proc* 1993;25:3012–3016. [PubMed: 8266433]
- [20]. Brockbank, KG.; Taylor, MJ. Tissue Preservation. In: Baust, JG.; Baust, JM., editors. *Advances in Biopreservation*. CRC Press; Boca Raton: 2007. p. 157-196.
- [21]. Busza AL, Fuller BJ, Proctor E, Gadian DG. The Time Course of Changes in Liver Phosphorus Metabolites during Hypothermic Preservation Measured by ³¹P Phosphorus Nuclear Magnetic Resonance. *Cryo-Letters* 1988;9(3):202–211.
- [22]. Carlsson PO, Palm F, Andersson A, Liss P. Chronically decreased oxygen tension in rat pancreatic islets transplanted under the kidney capsule. *Transplantation* 2000;69:761–766. [PubMed: 10755523]
- [23]. Carlsson PO, Palm F, Andersson A, Liss P. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. *Diabetes* 2001;50:489–495. [PubMed: 11246867]
- [24]. Carrel, A. Perfusing Media. In: Carrel, A.; Lindbergh, CA., editors. *The Culture of Organs*. Paul B. Hoeber, Inc.; New York: 1938. p. 55-74.
- [25]. Casavilla A, Ramirez C, Shapiro R, Nghiem D, Miracle K, Bronsther O, Randhawa P, Broznick B, Fung JJ, Starzl T. Experience with liver and kidney allografts from non-heart-beating donors. *Transplantation* 1995;59:197–203. [PubMed: 7839441]
- [26]. Castela AM, Grino JM, Gonzalez C, Franco E, GilVernet S, Andres R, Seron D, Torras J. Update of our experience in long-term renal function of kidneys transplanted from non-heart-beating cadaver donors. *Transplant Proc* 1993;25:1513–1515. [PubMed: 8442170]
- [27]. Cecka JM. The OPTN/UNOS renal transplant registry. *Clin.Transpl* 2004;1–16. [PubMed: 16704134]
- [28]. Cecka JM. The OPTN/UNOS Renal Transplant Registry. *Clin.Transpl* 2005;1–16. [PubMed: 17424721]
- [29]. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years-early events affecting transplant success. *Transplantation* 1992;53:59–64. [PubMed: 1733087]
- [30]. Cho YW, Terasaki PI, Cecka JM, Gjertson DW. Transplantation of kidneys from donors whose hearts have stopped beating. *N Engl J Med* 1998;338:221–225. [PubMed: 9435327]
- [31]. Cobert ML, West LM, Jessen ME. Machine perfusion for cardiac allograft preservation. *Curr.Opin.Organ Transplant* 2008;13:526–530. [PubMed: 19060537]
- [32]. Connolly JK, Dyer PA, Martin S, Parrott NR, Pearson RC, Johnson RWG. Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal preservation. *Transplantation* 1996;61:709–714. [PubMed: 8607172]
- [33]. Couch NP, Cassie GF, Murray JE. Survival of the excised dog kidney perfused in a pump-oxygenator system. I. Circulatory changes in the hypothermic preparation. *Surgery* 1958;44:666–682. [PubMed: 13592615]
- [34]. D'Alessandro AM, Hoffman RM, Belzer FO. Non-heart-beating donors: one response to the organ shortage. *Transplant Rev* 1995;9:168–176.
- [35]. Daemen JHC, DeVries B, Oomen APA, DeMeester J, Kootstra G. Effect of machine perfusion/preservation on delayed graft function in non-heart beating donor kidneys-early results. *Transpl Int* 1997;10:317–322. [PubMed: 9249943]

- [36]. Daemen JW, Oomen AP, Janssen MA, van de SL, van Kreel BK, Heineman E, Kootstra G. Glutathione S-transferase as predictor of functional outcome in transplantation of machine-preserved non-heart-beating donor kidneys. *Transplantation* 1997;63:89–93. [PubMed: 9000667]
- [37]. Danielewicz R, Kwiatkowski A, Polak W, Kosieradzki M, Michalak G, Wegrowicz I, Gaciong Z, Walaszewski J, Rowinski W. An assessment of ischemic injury of the kidney for transplantation during machine pulsatile preservation. *Transplant Proc* 1997;29:3580–3581. [PubMed: 9414845]
- [38]. Das, DK. Pathophysiology of Reperfusion Injury. CRC Press; Boca Raton: 1993.
- [39]. Davies DB, Harper A. The OPTN waiting list, 1988–2003. *Clin.Transpl* 2004;27–40. [PubMed: 16704136]
- [40]. De Loecker, W. Hypothermia and Preservation of Organs in the Liquid State. In: Fuller, BJ.; Grout, BWW., editors. *Clinical Applications of Cryobiology*. CRC Press; Boca Raton Ann Arbor Boston London: 1991. p. 46-79.
- [41]. Delmonico FL, Jenkins RL, Auchincloss H Jr, Etienne TJ, Russell PS, Monaco AB, Cosimi AB. Procurement of a whole pancreas and liver from the same cadaveric donor. *Surgery* 1989;105:718–723. [PubMed: 2658178]
- [42]. Dionne KE, Colton CK, Yarmush ML. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. *Diabetes* 1993;42:12–21. [PubMed: 8420809]
- [43]. Dutkowski P, de Rougemont O, Clavien PA. Machine perfusion for ‘marginal’ liver grafts. *Am.J.Transplant* 2008;8:917–924. [PubMed: 18416733]
- [44]. Dutkowski P, Odermatt B, Heinrich T, Schonfeld S, Watzka M, Winkelbach V, Krysiak M, Junginger T. Hypothermic oscillating liver perfusion stimulates ATP synthesis prior to transplantation. *J.Surg.Res* 1998;80:365–372. [PubMed: 9878339]
- [45]. Fitton TP, Barreiro CJ, Bonde PN, Wei C, Gage F, Rodriguez R, Conte JV. Attenuation of DNA damage in canine hearts preserved by continuous hypothermic perfusion. *Ann.Thorac.Surg* 2005;80:1812–1820. [PubMed: 16242460]
- [46]. Fitton TP, Wei C, Lin R, Bethea BT, Barreiro CJ, Amado L, Gage F, Hare J, Baumgartner WA, Conte JV. Impact of 24 h continuous hypothermic perfusion on heart preservation by assessment of oxidative stress. *Clin.Transplant* 2004;18(Suppl 12):22–27. [PubMed: 15217403]
- [47]. Florack G, Sutherland DE, Heil J, Squifflet JP, Najarian JS. Preservation of canine segmental pancreatic autografts: cold storage versus pulsatile machine perfusion. *J.Surg.Res* 1983;34:493–504. [PubMed: 6341715]
- [48]. Fujita S, Hamamoto I, Nakamura K, Tanaka K, Ozawa K. Evaluation of oxygen necessity during hypothermic liver perfusion. *Nippon Geka Hokan* 1993;62:228–240. [PubMed: 8031217]
- [49]. Fuller BJ, Busza AL, Proctor E. Possible Resuscitation of Liver Function by Reperfusion in vitro after Prolonged (24 hours) Cold Preservation: A ^{31}P NMR study. *Transplantation* 1990;50:511–513. [PubMed: 2402798]
- [50]. Fuller BJ, Gower JD, Green CJ. Free radical damage and organ preservation: fact or fiction? A review of the interrelationship between oxidative stress and physiological ion disbalance. *Cryobiology* 1988;25:377–393. [PubMed: 3058384]
- [51]. Fuller BJ, Lee CY. Hypothermic perfusion preservation: the future of organ preservation revisited? *Cryobiology* 2007;54:129–145. [PubMed: 17362905]
- [52]. Gonzalez-Segura C, Castelao AM, Torras J, Gil-Vernet S, Lopez-Costea MA, Riera L, Franco E, Fuuadosa X, Grino JM, Alsina J. Long term follow-up of transplanted non-heart-beating donor kidneys. *Transplant Proc* 1995;27:2948–2950. [PubMed: 7482974]
- [53]. Gotoh M, Maki T, Satomi S, Porter J, Monaco AP. Immunological characteristics of purified pancreatic islet grafts. *Transplantation* 1986;42:387–390. [PubMed: 3094210]
- [54]. Gravlee, GP.; Davis, RF.; Utley, JR. *Cardiopulmonary Bypass: Principles and Practice*. Williams & Wilkins; Baltimore Philadelphia: 1993.
- [55]. Groen H, Moers C, Smits JM, Treckmann J, van Gelder F, Rahmel A, Paul A, Pirenne J, Ploeg RJ, Buskens E. Cost-Effectiveness of Hypothermic Machine Perfusioin versus Static Cold Storage in Kidney Transplantation:First Results of the Prospective European RCT. *Transplantation Supplement* 2009;86(2S):93–94.
- [56]. Guarrera JV, Karim NA. Liver preservation: is there anything new yet? *Curr.Opin.Organ Transplant* 2008;13:148–154. [PubMed: 18685295]

- [57]. Hafez, T.; Fuller, B. Applications: Organ Preservation for Transplantation. In: Baust, John G.; Baust, John M., editors. *Advances in Biopreservation*. Taylor & Francis; Boca Raton: 2007. p. 197-270.
- [58]. Halliwell, B. Free Radicals and Human Disease- Trick or Treat?. In: Thomas, CE.; Kalyanaraman, B., editors. *Oxygen Radicals and the Disease Process*. Harwood Academic Publishers; Amsterdam: 1997. p. 1-14.
- [59]. Halloran P, Aprile M. A randomized prospective trial of cold storage versus pulsatile perfusion for cadaver kidney preservation. *Transplantation* 1987;43:827–832. [PubMed: 3590300]
- [60]. Hansen DK, Davies MI, Lunte SM, Lunte CE. Pharmacokinetic and metabolism studies using microdialysis sampling. *J.Pharm.Sci* 1999;88:14–27. [PubMed: 9874697]
- [61]. Hering BJ, Ricordi C. Islet transplantation for patients with type 1 diabetes: results, research priorities and reasons for optimism. *Graft* 1999;2:12–27.
- [62]. Hernandez A, Light JA, Barhyte DY, Mabudian M, Gage F. Ablating the ischemia-reperfusion injury in non-heart-beating donor kidneys. *Transplantation* 1999;67(2):200–206. [PubMed: 10075581]
- [63]. Huang JS, Downes GL, Childress GL, Felts JM, Belzer FO. Oxidation of ^{14}C -labelled substrates by Dog Kidney Cortex at 10 and 38°C. *Cryobiology* 1974;11(5):387–394. [PubMed: 4452273]
- [64]. Hume DM, Magee JH, Kauffman HM Jr. Rittenbury MS, Prout GR Jr. Renal homotransplantations in man in modified recipients. *Ann Surg* 1963;158:608–644. [PubMed: 14067508]
- [65]. Humphries AL Jr. Russell R, Christopher PE, Goodrich SM, Stoddard LD, Moretz WH. Successful Reimplantation Of Twenty-Four-Hour Stored Kidney To Nephrectomized Dog. *Ann.N.Y.Acad.Sci* 1964;120:496–505. [PubMed: 14235268]
- [66]. Humphries AL Jr. Russell R, Gregory J, Carter RH, Moretz WH. Hypothermic Perfusion Of The Canine Kidney For 48 Hours Followed By Reimplantation. *Am.Surg* 1964;30:748–752. [PubMed: 14217114]
- [67]. Humphries AL Jr. Russell R, Stoddard LD, Moretz WH. Successful five-day kidney preservation. Perfusion with hypothermic, diluted plasma. *Invest Urol* 1968;5:609–618. [PubMed: 4914852]
- [68]. Humphries AL Jr. Russell R, Stoddard LD, Moretz WH. Three-day kidney preservation: perfusion of kidneys with hypothermic, diluted blood of plasma. *Surgery* 1968;63:646–652. [PubMed: 4868848]
- [69]. Ikonovic M, Kelly KM, Hentosz TM, Shih SR, Armstrong DM, Taylor MJ. Ultraprofound Cerebral Hypothermia and Blood Substitution with an Acellular Synthetic Solution Maintains Neuronal Viability in Rat Hippocampus. *CryoLetters* 2001;22:19–26. [PubMed: 11788840]
- [70]. Iwamoto H, Matsuno N, Narumi Y, Uchiyama M, Kozaki K, Degawa H, Hama K, Kikuchi K, Takeuchi H, Kozaki M, Nagao T. Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. *Transplant Proc* 2000;32:1645–1646. [PubMed: 11119873]
- [71]. Jacobbi LM, McBride VA, Etheredge EE, McDonald JC, Feduska N, Frey DJ, Boudreaux JP, Van Meter C, McMillan R, Tesi RJ. Costs associated with expanding donor criteria; a collaborative statewide prospective study. *Transplant Proc* 1997;29:1550–1556. [PubMed: 9123422]
- [72]. Jain S, Lee CY, Baicu S, Duncan H, Xu H, Jones JW Jr. Clemens MG, Brassil J, Taylor MJ, Brockbank KG. Hepatic function in hypothermically stored porcine livers: comparison of hypothermic machine perfusion vs cold storage. *Transplant Proc* 2005;37:340–341. [PubMed: 15808637]
- [73]. Jain S, Lee SH, Korneszcuk K, Culberson CR, Southard JH, Berthiaume F, Zhang JX, Clemens MG, Lee CY. Improved preservation of warm ischemic livers by hypothermic machine perfusion with supplemented University of Wisconsin solution. *J.Invest Surg* 2008;21:83–91. [PubMed: 18340625]
- [74]. Johnson RW, Anderson M, Morley AR, Taylor RM, Swinney J. Twenty four-hour preservation of kidneys injured by prolonged warm ischemia. *Transplantation* 1972;13:174–179. [PubMed: 4550991]
- [75]. Karow AM, Carrier O. Effects of cryoprotectant compounds on mammalian heart muscle. *Surg Gynecol Obstet* 1969;128:571. [PubMed: 5777547]

- [76]. Karow AM Jr, Jeske AH. Functional preservation of the mammalian kidney. IV. Functional effects of perfusion with dimethyl sulfoxide (DMSO) at normothermia. *Cryobiology* 1976;13:448–454. [PubMed: 786550]
- [77]. Karow AM, Wiggins S, Carrier GO, et al. Functional preservation of the mammalian kidney. *J Surg Res* 1979;27:93–99. [PubMed: 379439]
- [78]. Ketchum RJ, Nicolae M, Jahr H, Friedman A, Naji A, Barker CF, Brayman KL. Analysis of donor age and cold ischemia time as factors in cadaveric human islet isolation. *Transplant.Proc* 1994;26:596–597. [PubMed: 8171574]
- [79]. Kievit JK, Nederstigt AP, Oomen AP, Janssen MA, Schoot L, Kootstra G. Release of alpha-glutathione S-transferase (alpha GST) and pi-glutathione S-transferase (pi GST) from ischemic damaged kidneys into the machine perfusate--relevance to viability assessment. *Transplant Proc* 1997;29:3591–3593. [PubMed: 9414850]
- [80]. Kievit JK, Oomen APA, Janssen MA, van Kreel BK, Heineman E, Kootstra G. Viability assessment of non-heart-beating donor kidneys by alpha glutathione S-transferase in the machine perfusate. *Transplant Proc* 1997;29:1381–1383. [PubMed: 9123348]
- [81]. Kim JS, Boudjema K, D'Alessandro A, Southard JH. Machine perfusion of the liver: maintenance of mitochondrial function after 48-hour preservation. *Transplant Proc* 1997;29:3452–3454. [PubMed: 9414787]
- [82]. Kootstra G. The asystolic, or non-heart-beating, donor. *Transplantation* 1997;63:917–921. [PubMed: 9112339]
- [83]. Kootstra G, Daemen JHC, Oomen APA. Categories of non-heart-beating donors. *Transplant Proc* 1995;27:2893–2894. [PubMed: 7482956]
- [84]. Koyama H, Cecka JM, Terasaki PI. A comparison of cadaver kidney storage methods: pump perfusion and cold storage solutions. *Clin Transplant* 1993;7:199–205.
- [85]. Kozaki K, Sakurai E, Nagao T, Kozaki M. Usefulness of continuous hypothermic perfusion preservation in renal transplantation from non-heart-beating donors. *Transplant Proc* 2002;34:2592–2597. [PubMed: 12431537]
- [86]. Kozaki K, Sakurai E, Uchiyama M, Matsuno N, Kozaki M, Nagao T. Usefulness of high-risk renal graft conditioning: functional improvement of high-risk grafts by addition of reagents to continuous hypothermic perfusion preservation solution. *Transplant Proc* 2000;32:164–166. [PubMed: 10701007]
- [87]. Kozaki M, Matsuno N, Tamaki T, Tanaka M, Kono K, Ito H, Uchiyama M, Tamaki I, Sakurai E. Procurement of kidney grafts from non-heart-beating donors. *Transplant Proc* 1991;23:2575–2578. [PubMed: 1926488]
- [88]. Kwiatkowski A, Wszola M, Kosieradzki M, Danielewicz R, Ostrowski K, Domagala P, Lisik W, Nosek R, Fesolowicz S, Trzebicki J, Durlik M, Paczek L, Chmura A, Rowinski W. Machine perfusion preservation improves renal allograft survival. *Am.J.Transplant* 2007;7:1942–1947. [PubMed: 17617857]
- [89]. Lakey JR, Rajotte RV, Warnock GL, Kneteman NM. Human pancreas preservation prior to islet isolation. Cold ischemic tolerance. *Transplantation* 1995;59:689–694. [PubMed: 7886793]
- [90]. Lakey JRT, Burridge PW, Shapiro AMJ. Technical aspects of islet preparation and transplantation. *Transpl Int* 2003;16:613–632. [PubMed: 12928769]
- [91]. Lakey, JRT.; Kobayashi, N.; Shapiro, AMJ.; Ricordi, C.; Okitsu, T. *Current Human Islet Isolation Protocol*. Medical Review Co. Ltd.; Chuo-ku, Osaka: 2004.
- [92]. Lameris TW, van Den Meiracker AH, Boomsma F, Alberts G, de Zeeuw S, Duncker DJ, Verdouw PD, Veld AJ. Catecholamine handling in the porcine heart: a microdialysis approach. *Am.J.Physiol* 1999;277:H1562–H1569. [PubMed: 10516196]
- [93]. Lanir A, Clouse ME, Lee RG. Liver preservation for transplant. Evaluation of hepatic energy metabolism by ³¹P NMR. *Transplantation* 1987;43:786–790. [PubMed: 3109086]
- [94]. Lauschke H, Olschewski P, Tolba R, Schulz S, Minor T. Oxygenated machine perfusion mitigates surface antigen expression and improves preservation of predamaged donor livers. *Cryobiology* 2003;46:53–60. [PubMed: 12623028]

- [95]. Lazzarino G, Nuutinen ME, Tavazzi B, Cerroni L, Di Pierro D, Giardina B. Preserving effect of fructose-1,6-bisphosphate on high-energy phosphate compounds during anoxia and reperfusion in isolated Langendorff-perfused rat hearts. *J Mol Cell Cardiol* 1991;23:13–23. [PubMed: 2038067]
- [96]. Lee, CY.; Duncan, HM.; Jain, S.; Jones, J.; Zhang, JX.; Jones, JW.; Clemens, MG. Recovery of Energy Stores of Non-heart-beating Donor Livers Following Preservation by Hypothermic Machine Perfusion; Proceedings of the 2003 International Mechanical Engineering Congress and Exposition; 2003;
- [97]. Lee CY, Jain S, Duncan HM, Zhang JX, Jones JW Jr. Southard JH, Clemens MG. Survival transplantation of preserved non-heart-beating donor rat livers: preservation by hypothermic machine perfusion. *Transplantation* 2003;76:1432–1436. [PubMed: 14657681]
- [98]. Leeser DB, Bingaman AW, Poliakova L, Shi Q, Gage F, Bartlett ST, Farney AC. Pulsatile pump perfusion of pancreata before human islet cell isolation. *Transplant Proc* 2004;36:1050–1051. [PubMed: 15194365]
- [99]. Leibach FH, Fonteles MC, Pillion D, Karow AM Jr. Glutathione in the isolated perfused rabbit kidney. *J.Surg.Res* 1974;17:228–231. [PubMed: 4417975]
- [100]. Levy MV. Oxygen consumptions and blood flow in the hypothermic perfused kidney. *Am.J.Physiol* 1959;197:1111–1114. [PubMed: 14416432]
- [101]. Lindbergh CA, Perry VP, Malinin TI, Mouer GH. An apparatus for the pulsating perfusion of whole organs. *Cryobiology* 1966;3:252–260. [PubMed: 4961508]
- [102]. Lockett CJ, Fuller BJ, Busza AL, Proctor E. Hypothermic perfusion preservation of liver: the role of phosphate in stimulating ATP synthesis studied by ³¹P NMR. *Transpl Int* 1995;8:440–445. [PubMed: 8579734]
- [103]. Matsuno N, Konno O, Mejit A, Jyojima Y, Akashi I, Nakamura Y, Iwamoto H, Hama K, Iwahori T, Ashizawa T, Nagao T. Application of machine perfusion preservation as a viability test for marginal kidney graft. *Transplantation* 2006;82:1425–1428. [PubMed: 17164712]
- [104]. Matsuno N, Kozaki K, Degawa H, Narumi Y, Suzuki N, Kikuchi K, Uchiyama M, Kubota K, Sakurai E, Kozaki M, Nagao T. A useful predictor in machine perfusion preservation for kidney transplantation from non-heart-beating donors. *Transplant Proc* 2000;32:173–174. [PubMed: 10701011]
- [105]. Matsuno N, Sakurai E, Tamaki I, Uchiyama M, Kozaki K, Kozaki M. Effect of machine perfusion preservation on delayed graft function in non-heart-beating donors. *Transplantation* 1994;57:293–294. [PubMed: 8310523]
- [106]. Matsuno N, Sakurai KE, Iwahori UT, Kono KK, Tanaka M, Tamaki T, Tamaki I. Effect of Combination In Situ Cooling and Machine Perfusion Preservation on Non-Heart-Beating Donor Kidney Procurement. *Transplant Proc* 1993;25:1516–1517. [PubMed: 8442171]
- [107]. Matsuoka L, Shah T, Aswad S, Bunnapradist S, Cho Y, Mendez RG, Mendez R, Selby R. Pulsatile perfusion reduces the incidence of delayed graft function in expanded criteria donor kidney transplantation. *Am.J.Transplant* 2006;6:1473–1478. [PubMed: 16686773]
- [108]. McAnulty JF, Ploeg RJ, Southard JH, Belzer FO. Successful Five-Day Perfusion Preservation of the Canine Kidney. *Transplantation* 1989;47:37–41. [PubMed: 2643229]
- [109]. McKay DB, Karow AM. A functional analysis on isolated rat islets of Langerhans: effects of dimethylsulfoxide and low-temperature preservation. *Cryobiology* 1983;20:41–50. [PubMed: 6339171]
- [110]. Merion RM, Oh HK, Port FK, Toledo-Pereyra LH, Turcotte JG. A prospective controlled trial of cold-storage versus machine-perfusion preservation in cadaveric renal transplantation. *Transplantation* 1990;50:230–233. [PubMed: 2382290]
- [111]. Minor T, Vollmar B, Klauke H, Isselhard W, Menger MD. differential effect of preservative solutions (UW vs HTK) on mitochondrial redox status and energy metabolism during liver ischemia with oxygen persufflation. *Langenbecks Arch Chir Suppl Kongressbd* 1998;15(Suppl I):377–381. [PubMed: 14518279]
- [112]. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, Kasterop-Kutz M, van der Heide JJ, Squifflet JP, van Heurn E, Kirste GR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ. Machine perfusion or cold storage in deceased-donor kidney transplantation. *N.Engl.J.Med* 2009;360:7–19. [PubMed: 19118301]

- [113]. Monbaliu D, Vekemans K, De Vos R, Brassil J, Heedfeld V, Qiang L, D'hollander M, Roskams T, Pirenne J. Hemodynamic, biochemical, and morphological characteristics during preservation of normal porcine livers by hypothermic machine perfusion. *Transplant Proc* 2007;39:2652–2658. [PubMed: 17954200]
- [114]. Monbaliu D, Vekemans K, Liu Q, Heedfeld V, Wylin T, Van Breussegem A, Pirenne J. Liver transplantation from non-heart-beating donors: current status and future prospects in an experimental model. *Acta Chir Belg* 2008;108:45–51. [PubMed: 18411572]
- [115]. Moustafellos P, Hadjianastassiou V, Roy D, Muktedir A, Contractor H, Vaidya A, Friend PJ. The influence of pulsatile preservation in kidney transplantation from non-heart-beating donors. *Transplant Proc* 2007;39:1323–1325. [PubMed: 17580131]
- [116]. Navarro AP, Sohrabi S, Reddy M, Carter N, Ahmed A, Talbot D. Dual transplantation of marginal kidneys from nonheart beating donors selected using machine perfusion viability criteria. *J Urol* 2008;179:2305–2309. [PubMed: 18423701]
- [117]. Nicholson ML, Hosgood SA, Metcalfe MS, Waller JR, Brook NR. A comparison of renal preservation by cold storage and machine perfusion using a porcine autotransplant model. *Transplantation* 2004;78:333–337. [PubMed: 15316359]
- [118]. Nishiyama A, Majid DS, Taher KA, Miyatake A, Navar LG. Relation between renal interstitial ATP concentrations and autoregulation-mediated changes in renal vascular resistance. *Circ Res* 2000;86:656–662. [PubMed: 10747001]
- [119]. Nishiyama A, Miura K, Miyatake A, Fujisawa Y, Yue W, Fukui T, Kimura S, Abe Y. Renal interstitial concentration of adenosine during endotoxin shock. *Eur J Pharmacol* 1999;385:209–216. [PubMed: 10607878]
- [120]. Nowak G, Ungerstedt J, Wernerman J, Ungerstedt U, Ericzon BG. Metabolic changes in the liver graft monitored continuously with microdialysis during liver transplantation in a pig model. *Liver Transpl* 2002;8:424–432. [PubMed: 12004341]
- [121]. O'Neil JJ, Stegemann JP, Nicholson DT, Gagnon KA, Solomon BA, Mullon CJ. The isolation and function of porcine islets from market weight pigs. *Cell Transplant* 2001;10:235–246. [PubMed: 11437069]
- [122]. Opelz G, Wujciak T. Comparative analysis of kidney preservation methods. *Transplant Proc* 1996;28:87–90. [PubMed: 8644351]
- [123]. Orloff MS, Reed AI, Erturk E, Kruk RA, Paprocki SA, Cimbalo SC, Cerilli GJ. Non-heart-beating cadaveric organ donation. *Ann Surg* 1994;220:578–583. [PubMed: 7944668]
- [124]. Osgood R, Kaczowka K, Lewis R. The Use of a Novel Monitoring Apparatus and Modified Belzer Hydroxyethyl Starch Perfusate for Analysis of Glomerular Filtration During Hypothermic Perfusion Preservation. *Transplantation* 1996;62:1734–1739. [PubMed: 8990353]
- [125]. Pegg DE, Wusteman MC, Foreman J. Metabolism of Normal and Ischemically Injured Rabbit Kidneys During Perfusion for 48 Hours at 10 C. *Transplantation* 1981;32:437–443. [PubMed: 7330963]
- [126]. Peltz M, Cobert ML, Rosenbaum DH, West LM, Jessen ME. Myocardial perfusion characteristics during machine perfusion for heart transplantation. *Surgery* 2008;144:225–232. [PubMed: 18656629]
- [127]. Pienaar BH, Lindell SL, Van Gulik T, Southard JH, Belzer FO. Seventy-Two-Hour Preservation of the Canine Liver by Machine Perfusion. *Transplantation* 1990;49:258–260. [PubMed: 2305453]
- [128]. Polyak MMR, Arrington MO, Stubenbord WT, Boykin J, Brown T, Jean-Jacques MA, Estevez J, Kapur S, Kinkhabwala M. Influence of Pulsatile Preservation on Renal Transplantation in the 1990's. *Transplantation* 2000;69(2):249–258. [PubMed: 10670635]
- [129]. Polyak MMR, Arrington MO, Stubenbord WT, Kapur S, Kinkhabwala M. Prostaglandin E1 influences pulsatile preservation characteristics and early graft function in the expanded criteria donor kidneys. *Journal of Surgical Research* 1999;85:17–25. [PubMed: 10383833]
- [130]. Qayumi AK, Jamieson WRE, Rosado LJ, Tomlinson CW, Schulzer M, McConville B, Gillespie K, Wong A. Preservation techniques for heart transplantation: comparison of hypothermic storage and hypothermic perfusion. *J Heart Lung Transplant* 1991;10:518–526. [PubMed: 1911794]
- [131]. Rauen U, De Groot H. New Insights into the Cellular and Molecular Mechanisms of Cold Storage Injury. *J Invest Medicine* 2004;52(5):299–309.

- [132]. Reznik ON, Bagnenko SF, Loginov IV, Iljina VA, Ananyev AN, Eremich SV, Moysyuk YG. Machine perfusion as a tool to select kidneys recovered from uncontrolled donors after cardiac death. *Transplant Proc* 2008;40:1023–1026. [PubMed: 18555105]
- [133]. Reznik ON, Bagnenko SF, Loginov IV, Moisiuk YG. Increasing kidneys donor's pool by machine perfusion with the LifePort--pilot Russian study. *Ann.Transplant* 2006;11:46–48. [PubMed: 17494299]
- [134]. Rhee P, Talon E, Eifert S, Anderson D, Stanton K, Koustova E, Ling G, Burris D, Kaufmann C, Mongan P, Rich NM, Taylor MJ. Induced Hypothermia during emergency department thoractomy: an animal model. *J Trauma* 2000;48:439–447. [PubMed: 10744281]
- [135]. Ricordi, C.; Hering, B.; London, NJ.; Rajotte, RV.; Gray, DWR.; Socci, C.; Alejandro, R.; Carroll, PB.; Bretzel, RG.; Scharp, DW. Islet Isolation Assessment. In: Ricordi, C., editor. *Pancreatic Islet Cell Transplantation*. R.G. Landes; Austin: 1992. p. 132-142.
- [136]. Robertson GS, Chadwick D, Thirdborough S, Swift S, Davies J, James R, Bell PR, London NJ. Human islet isolation--a prospective randomized comparison of pancreatic vascular perfusion with hyperosmolar citrate or University of Wisconsin solution. *Transplantation* 1993;56:550–553. [PubMed: 8212148]
- [137]. Ryan EA, Lakey JR, Rajotte RV, Korbitt GS, Kin T, Imes S, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. *Diabetes* 2001;50:710–719. [PubMed: 11289033]
- [138]. Safar PJ, Tisherman SA. Suspended animation for delayed resuscitation. *Curr.Opin.Anaesthesiol* 2002;15:203–210. [PubMed: 17019202]
- [139]. Safar PJ, Tisherman SA. Trauma resuscitation: what have we learned in the last 50 years? *Curr.Opin.Anaesthesiol* 2003;16:133–138. [PubMed: 17021451]
- [140]. Schlumpf R, Weber M, Weinreich T, Spahn D, Rothlin M, Candinas D. Transplantation of kidneys from non-heart-beating donors: an update. *Transplant Proc* 1996;28:107–109. [PubMed: 8644134]
- [141]. Schold JD, Kaplan B, Howard RJ, Reed AI, Foley DP, Meier-Kriesche HU. Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation. *Am.J.Transplant* 2005;5:1681–1688. [PubMed: 15943626]
- [142]. Shapiro AMJ, Ricordi C, Hering B, et al. International Multi-center Trial of islet Transplantation using the Edmonton Protocol in Patients with Type I Diabetes. *Transplantation* 2004;78(2):176.
- [143]. Siesjo, BK. The Role of Calcium in Cell Death. In: Price, DL.; Thoenen, H.; Aguayo, AJ., editors. *Neurodegenerative Disorders: Mechanisms and Prospects for Therapy*. John Wiley & Sons Ltd.; 1991. p. 35-59.
- [144]. Slapak M, Wigmore RA, MacLean LD. Twenty-four hour liver preservation by the use of continuous pulsatile perfusion and hyperbaric oxygen. *Transplantation* 1967;5(Suppl-8)
- [145]. So PW, Fuller BJ. A comparison of the metabolic effects of continuous hypothermic perfusion or oxygenated persufflation during hypothermic storage of rat liver. *Cryobiology* 2001;43:238–247. [PubMed: 11888217]
- [146]. Southard, JH.; Ametani, MS. Organ Preservation. In: Ginns, LC.; Cosimi, AB.; Morris, P., editors. *Blackwell Scientific*; Cambridge, MA: 1998. p. 271-281.
- [147]. Starzl TE, Marchiro TL, Brittain RS, Holmes JH, Wandell WR. Problems in renal homotransplantations. *JAMA* 1964;187:734–740. [PubMed: 14094295]
- [148]. Stratta RJ, Moore PS, Farney AC, Rogers J, Hartmann EL, Reeves-Daniel A, Gautreaux MD, Iskandar SS, Adams PL. Influence of pulsatile perfusion preservation on outcomes in kidney transplantation from expanded criteria donors. *J.Am.Coll.Surg* 2007;204:873–882. [PubMed: 17481502]
- [149]. Stubenitsky BM, Ametani M, Danielewicz R, Southard JH, Belzer FO. Regeneration of ATP in kidney slices after warm ischemia and hypothermic preservation. *Transpl Int* 1995;8:293–297. [PubMed: 7546152]
- [150]. Sung RS, Christensen LL, Leichtman AB, Greenstein SM, Distant DA, Wynn JJ, Stegall MD, Delmonico FL, Port FK. Determinants of discard of expanded criteria donor kidneys: impact of biopsy and machine perfusion. *Am.J.Transplant* 2008;8:783–792. [PubMed: 18294347]

- [151]. Sung RS, Galloway J, Tuttle-Newhall JE, Mone T, Laeng R, Freise CE, Rao PS. Organ donation and utilization in the United States, 1997-2006. *Am.J.Transplant* 2008;8:922–934. [PubMed: 18336696]
- [152]. Szust J, Olson L, Cravero L. A comparison of OPO pulsatile machine preservation practices and results. *J.Transpl.Coord* 1999;9:97–100. [PubMed: 10703389]
- [153]. Tanioka Y, Sutherland DE, Kuroda Y, Suzuki Y, Matsumoto I, Deai T. Preservation of dog pancreas before islet isolation with the two-layer method. *Transplant.Proc* 1998;30:3419–3420. [PubMed: 9838507]
- [154]. Tavazzi B, Cerroni L, Di Pierro D, Lazzarino G, Nuutinen M, Starnes JW, Giardina B. Oxygen radical injury and loss of high-energy compounds in anoxic and reperfused rat heart: prevention by exogenous fructose-1,6-bisphosphate. *Free Radic Res Commun* 1990;10:167–176. [PubMed: 2397920]
- [155]. Tavazzi B, Starnes JW, Lazzarino G, Di Pierro D, Nuutinen EM, Giardina B. Exogenous fructose-1,6-bisphosphate is a metabolizable substrate for the isolated normoxic rat heart. *Basic Res Cardiol* 1992;87:280–289. [PubMed: 1520250]
- [156]. Taylor, MJ.; Cryomedical Sciences, Inc.. Solutions for Tissue Preservation and Bloodless Surgery and Methods Using Same. US Patent. # [5,405,742]. 1995. Assigned to
- [157]. Taylor, MJ.; Organ Recovery Systems, Inc.. System for Organ and Tissue Preservation and Hypothermic Blood Substitution. US Patent. # [6,492,103]. 2002. Assigned to
- [158]. Taylor, MJ. Biology of cell survival in the cold: The Basis for Biopreservation of Tissues and Organs. In: Baust, JG.; Baust, JM., editors. *Advances in Biopreservation*. CRC Press; Boca Raton: 2007. p. 15-62.
- [159]. Taylor, MJ. Hypothermia. In: Fink, G., editor. *Encyclopedia of Stress*. Academic Press; Oxford: 2007. p. 428-438.
- [160]. Taylor MJ. Hypothermic Blood Substitution: Special Considerations for Protection of Cells during ex vivo and in vivo Preservation. *Transfusion Medicine and Hemotherapy* 2007;34:226–244.
- [161]. Taylor, MJ.; Baicu, S. Hypothermic Perfusion of Pancreas: Emphasis on Preservation prior to Islet Isolation. In: Lee, CY.; Yarmush, Martin; Langer, Robert, editors. *Organ Perfusion Preservation, Methods in Bioengineering*. Artech House Publisher; Boston: 2010. In Press
- [162]. Taylor MJ, Baicu S, Greene E, Vazquez A, Brassil J. Viable Yield of Islets from Ischemic Porcine Pancreata is Improved Using Twenty-Four Hour Hypothermic Machine Perfusion Preservation. *Transplantation* 2008;86:369. [PubMed: 18645507]
- [163]. Taylor MJ, Baicu S, Leman B, Greene E, Vazquez A, Brassil J. Twenty-four hour hypothermic machine perfusion of porcine pancreas facilitates processing for islet isolation. *Transplant Proc* 2008;40:480–482. [PubMed: 18374108]
- [164]. Taylor MJ, Baicu SC, Greene E, Vazquez A, Brassil J. Islet Isolation from Juvenile Porcine pancreas after 24-Hour Hypothermic Machine Perfusion preservation: Effect of Preservation Solution and Warm Ischemia. *Cell Transplantation*. 2009 In Press.
- [165]. Taylor MJ, Bailes JE, Elrifai AM, Shih S-R, Teeple E, Leavitt ML, Baust JG, Maroon JC. A New Solution for Life Without Blood: Asanguineous Low Flow Perfusion of a Whole-body Perfusate during 3 hours of Cardiac Arrest and Profound Hypothermia. *Circulation* 1995;91:431–444. [PubMed: 7805248]
- [166]. Taylor, MJ.; Brassil, J.; Organ Recovery Systems, Inc.. Method for perfusing an organ and for isolating cells from the organ. US Patent. # [7504201]. 2009. Assigned to
- [167]. Taylor, MJ.; Brockbank, KGM. Frontiers in Biopreservation Technology: Challenges for the Storage of Living Tissues and Engineered Constructs. In: Klatz, R.; Goldman, R., editors. *Anti-Aging Medical Therapeutics*. A4M Publications; Chicago: 2003. p. 515-526.
- [168]. Taylor, MJ.; Elrifai, AM.; Bailes, JE. Hypothermia in Relation to the Acceptable Limits of Ischemia for Bloodless Surgery. In: Steponkus, PL., editor. *Advances in Low Temperature Biology*. JAI Press; London, UK Greenwich,CT: 1996. p. 1-64.
- [169]. Taylor MJ, Rhee P, Chen Z, Alam HB. Design of Preservation Solutions for Universal Tissue Preservation in vivo: Demonstration of Efficacy in Pre-clinical Models of Profound Hypothermic Cardiac Arrest. *Transpl Proc* 2005;37:303–307.

- [170]. Taylor MJ, Soleto E, Aultman D, Mancini MC, Moulder PV, Owen D, Shih T, Brockbank KGM. Preclinical Evaluation of Unisol: A Single Solution for Both Flush and Perfusion Preservation Preservation of Organs for Transplantation. *Cryobiology* 2000;41:360.
- [171]. Taylor MJ, Song YC, Chen ZZ, Lee FS, Brockbank KG. Interactive Determinants for Optimized Stabilization of Autologous Vascular Grafts during Surgery. *Cell Preservation Technology* 2004;2(3):198–208.
- [172]. Tersigni R, Toledo-Pereyra LH, Pinkham J, Najarian JS. Pancreaticoduodenal preservation by hypothermic pulsatile perfusion for twenty-four hours. *Ann.Surg* 1975;182:743–748. [PubMed: 1103762]
- [173]. Toledo-Pereyra LH, Valgee KD, Castellanos J, Chee M. Hypothermic pulsatile perfusion: its use in the preservation of pancreases for 24 to 48 hours before islet cell transplantation. *Arch.Surg* 1980;115:95–98. [PubMed: 6766062]
- [174]. Tullius SG, Garcia-Cardena G. Organ procurement and perfusion before transplantation. *N.Engl.J.Med* 2009;360:78–80. [PubMed: 19118308]
- [175]. van der Plaats A, 't Hart NA, Verkerke GJ, Leuvenink HG, Ploeg RJ, Rakhorst G. Hypothermic machine preservation in liver transplantation revisited: concepts and criteria in the new millennium. *Ann.Biomed Eng* 2004;32:623–631. [PubMed: 15117035]
- [176]. van der Plaats A, Maathuis MH, 't Hart NA, Bellekom AA, Hofker HS, van der Houwen EB, Verkerke GJ, Leuvenink HG, Verdonck P, Ploeg RJ, Rakhorst G. The Groningen hypothermic liver perfusion pump: functional evaluation of a new machine perfusion system. *Ann.Biomed.Eng* 2006;34:1924–1934. [PubMed: 17066322]
- [177]. Varty K, Veitch PS, Morgan JD, Bell PR. Kidney retrieval from asystolic donors: a valuable and viable source of additional organs. *Br J Surg* 1994;81:1459–1460. [PubMed: 7820470]
- [178]. Vekemans K, Liu Q, Brassil J, Komuta M, Pirenne J, Monbaliu D. Influence of flow and addition of oxygen during porcine liver hypothermic machine perfusion. *Transplant Proc* 2007;39:2647–2651. [PubMed: 17954199]
- [179]. Vekemans K, Liu Q, Pirenne J, Monbaliu D. Artificial circulation of the liver: machine perfusion as a preservation method in liver transplantation. *Anat.Rec.(Hoboken.)* 2008;291:735–740. [PubMed: 18484620]
- [180]. Webb WR, Karow A Jr. Hypothermic Organ Preservation: Comparison Of Cooling And Warming Methods. *JAMA* 1965;191:1012–1014. [PubMed: 14257727]
- [181]. Wight J, Chilcott J, Holmes M, Brewer N. The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors. *Health Technol.Assess* 2003;7:1–94. [PubMed: 14499050]
- [182]. Wijnen RM, Booster MH, Stubenitsky BM, de Boer J, Heineman E, Kootstra G. Outcome of transplantation of non-heart-beating donor kidneys. *Lancet* 1995;345:1067–1070. [PubMed: 7715337]
- [183]. Wikstrom G, Ronquist G, Nilsson S, Maripu E, Waldenstrom A. Continuous monitoring of energy metabolites using microdialysis during myocardial ischaemia in the pig. *Eur.Heart J* 1995;16:339–347. [PubMed: 7789376]
- [184]. Zhou, YC.; Cecka, JM. Effect of HLA matching on renal transplant survival. In: Terasaki, PI.; Cecka, JM., editors. *Clinical Transplants*. UCLA Tissue Typing Laboratory; Los Angeles: 1993. p. 499-510.

Figure 1.

Progressive annual increase in the percentage of clinical donor kidneys perfused prior to transplantation. It is clear that the highest proportion of “pumped” kidneys is found in the DCD (formerly labeled NHBD) category followed by the ECD group. In recent years, the percentage of organs in the Standard Criteria Donors (SCD) has also begun to increase. The reasons for these trends are explained in the text. [Data from the OPTN/UNOS Registry reports [151]]

Figure 2.

Diagram illustrating the unmet demand for donor transplant organs. There is an ever widening gap between supply and demand as illustrated by the current (USA plus Europe) and forecasted numbers for kidney transplants in the top panel. The lower panel illustrates the fact that today the vast majority of transplanted kidneys are recovered from living-related donors or heart-beating cadavers [151]. The diagram also illustrates the point that there is now a recognized opportunity to increase the donor pool by considering the use of “expanded criteria organs” from heart-beating donors, or recovering organs from NHBDs as discussed in the text.

Figure 3.

a. Schematic representation of the placement of a microdialysis probe (not to scale) in the renal cortex for sampling of the interstitial fluid. This technique is proposed as one means of improving the assessment of the quality of donor organs during the storage interval [8].

b. Renal pyruvate concentration during hypothermic machine perfusion, as a function of time. Statistically significant higher pyruvate concentrations ($p < 0.05$) were detected in the interstitial fluid relative to renal effluent. Data were collected using the microdialysis technique depicted in panel a. and are presented as the mean $\pm$ SEM. ($n = 4$ for the control group and $n = 8$ for the FDP group).

Figure 4.

Hypothermic perfusion preservation of a porcine pancreas on a LifePort machine. The upper panel shows the features of the LifePort including, 1. Ice chamber; 2. Organ cassette; 3. The tubing frame, which includes pressure and bubble sensors; 4. The pump head; and 5. The user-friendly control panel. The lower panel shows the details of a pig pancreas installed in the perfusion cassette and hooked up to the perfusion inlet line via a seal-ring cannula (arrowed). This proprietary cannula allows simultaneous perfusion of the celiac trunk (CT) and superior mesenteric artery (SMA) by way of an aortic patch clamped in the seal-ring cannula (see inset) [164]. The inset photo shows the opening of the CT and SMA in the aortic patch (AP), which was exposed for viewing by opening the seal-ring cannula.

Figure 5.

Physical parameters (Flow, Resistance and Perfusate Temperature) measured on the LifePort perfusion machine during 24h hypothermic perfusion of a porcine pancreas. Pancreas weight = 87g; the level of edema after 24h = 139%, and the islet yield = 247,950 IE (Islet Equivalents; IE are determined using the universally accepted standard convention for quantifying islets, which inherently have a wide distribution of sizes ranging from $<50\mu\text{m}$ to $>400\mu\text{m}$ diameter [135]).

Figure 6.
Effect of HPP on islet yield expressed as islet equivalents (IE) per gram of digested pancreas (mean $\pm$ SEM).

Table 1
Catalogue of ischemia-related events influenced by hypothermia [158-160]

Ischemic events affected by hypothermia	Principal Effects
General suppression of reaction rates	<ol style="list-style-type: none"> 1 Slows metabolism and demand for oxygen 2 Reduces rate of substrate & energy depletion 3 Attenuates chemical processes that cause ischemic injury.
Metabolic uncoupling	Dislocation of integrated biochemical pathways
Energy metabolism	Complex shifts from aerobic to anaerobic alter substrate dependencies and determine optimum temperature for preservation
Ion Transport and Cell Swelling	Passive redistribution of ions and water across cell membranes demands counteractive measures.
Proton activity changes	pH regulation changes demand effective buffering
Generation of oxygen-derived Free Radicals (ODFR)	Increased susceptibility of cells to generate ODFR and attenuates natural defense mechanisms.
Structural changes	<ol style="list-style-type: none"> 1 Membrane phase changes and loss of phospholipids. 2 Thermal shock. 3 Induction of stress proteins 4 Cytoskeletal changes
Mode of cell death	Apoptosis or necrosis

Table 2
Top Ten Benefits of Hypothermic Perfusion Preservation

<ul style="list-style-type: none">• Maintains the patency of the vascular bed• Provides nutrients, and low demand O₂ to support reduced energy demands• Removes metabolic by-products and toxins• Provides access for administration of cytoprotective agents and/or immunomodulatory drugs• Increases available assays for organ viability checks• Can facilitate change from emergency to elective surgery with reduced costs and improved outcomes• Improves outcomes as demonstrated by reduced Primary Non-Function and Delayed Graft Function• Permits use of expanded criteria kidneys, or organs from non-heart-beating donors to increase donor pool• Economic benefit for transplant centers & reduces health care costs• Provides technology for ex vivo use of non-transplanted organs for pharmaceutical research
--

Table 3

Categories of Non-heart beating donors: The Maastrich Classification [83]

Category	Description	Location	Potential Contribution
I	Dead on arrival	Outside hospital, Emergency room	?
II	Unsuccessful resuscitation	Emergency room, Intensive care	+++
III	Awaiting cardiac arrest	Intensive care	++
IV	Cardiac arrest while brain dead	Intensive care	±

Table 4**Islet Yield and Function Indices**

PANCREAS/ISLET CHARACTERISTICS	FRESH (untreated control) [N=7]	SCS (Viaspan) [N=9]	HMP (KPS-1) [N=7]	30WIT [N=6]	30WIT/HMP (KPS-1) [N=7]
Post-preservation edema (%)	-	-2.8±0.7	138±19	-	127±21
Total islet yield (IE x1000)	117±31	75±16	188±37*	158±27	127±22
Insulin Stimulation Index	4.6±1.3	2.5±0.4	2.9±0.4	6.2±2.2	4.2±0.4
20mM-glucose stimulated insulin release [ng/mL/ IE]	0.33±0.15	0.20±0.05	0.23±0.08	0.22±0.02	0.36±0.05
Insulin content [ng/mL/ IE]	8.51±3.68	4.75±1.00	11.80±3.79*	5.41±0.76	6.56±1.06

* p<0.05 vs. SCS